

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di valutazione per la chiamata a professore di II fascia da ricoprire ai sensi dell'art. 24, comma 6, della Legge n. 240/2010 per il settore concorsuale 06/D6 - Neurologia, (settore scientifico-disciplinare MED/26 - Neurologia) presso il Dipartimento di Fisiopatologia medico-Chirurgica e dei Trapianti, Codice concorso 3649

Elio Angelo Scarpini
CURRICULUM VITAE

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

| | |
|------------------------|--------------------|
| COGNOME | SCARPINI |
| NOME | ELIO ANGELO |
| DATA DI NASCITA | 12-07-1952 |

Titoli di studio

1971: Diploma Maturità Classica

1977: Laurea Medicina e Chirurgia (110/110 e lode) presso l'Università degli Studi di Milano.

1977: Abilitazione professione Medico Chirurgo presso l'Università degli Studi di Milano

1981: Specializzazione in Neurologia (70/70 e lode) presso l'Università degli Studi di Milano.

1989: Idoneità Nazionale per Primario nella disciplina Neurologia

2014: Abilitazione Scientifica per Professore I fascia (Ordinario) nel settore MED26-Neurologia (da 3/2/2014; scadenza 3/2/2020)

Esperienza professionale

1980-2003: Dirigente medico Neurologo IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico

1995-2007: Professore a Contratto, Scuola di Specializzazione in Neurologia, Università di Milano

2003-2013: Responsabile UOS Malattie Neurodegenerative e Demielinizzanti dell'IRCCS Fondazione Cà Granda

2007-oggi: Professore Associato di Neurologia (MED/26), Facoltà di Medicina e Chirurgia, Università di Milano.

2013-oggi: Direttore della UOSD Neurologia-Malattie Neurodegenerative e del relativo Laboratorio di Diagnostica Neurochimica e Genetica Molecolare

Attività didattica

1) Frontale nei corsi di Laurea a ciclo unico e specialistico e scuole specializzazione dell'Università di Milano:

- 2009-oggi: titolare dell'insegnamento semestrale di Neurologia per il IV anno corso di Laurea Magistrale in Odontoiatria e Protesi Dentaria (20 ore)
- 2002-oggi: lezioni sul tema Alzheimer e Sclerosi Multipla nell'ambito del V anno dell'insegnamento di Neurologia del corso di Laurea in Medicina e Chirurgia (Polo Centrale Policlinico: 8 ore; Ospedale S. Giuseppe: 8 ore)
- Scuola di Specializzazione in Neurologia: I anno Semeiotica Neurologica (4 ore); V anno Terapia Neurologica (8 ore)
- Scuola di Specializzazione in Reumatologia ed Immunologia (2 ore)

2) Relatore/correlatore di oltre 30 tesi del corso di Laurea in Medicina e Chirurgia negli ultimi 15 anni
Relatore/correlatore di oltre 10 tesi di Dottorato negli ultimi 15 anni (fino al 2007: Dottorato in Scienze Neurologiche e del Dolore, in seguito Dottorato di Medicina Molecolare e Traslazionale)

3) Tutoraggio dottorandi: dal 2001 in media 1 dottorando/anno

Pubblicazioni su riviste internazionali censite

1. Caccia MR, Cerri C, Gravame V, Meola G, Pagni R, Scarlato G, Scarpini E. Myopathy with paroxysmal myoglobinuria and focal muscle necrosis following enflurane anaesthesia. **Journal of the Neurological Sciences** 1978; 39(1):61-9.
2. Scarlato G, Meola G, Scarpini E, Cerri C. Muscular carnitine synthesis and palmitate metabolism in vitro. **Journal of Neurology** 1978; 218(3):149-56.
3. Meola G, Manfredi L, Scarpini E, Dall'Oglio P, Mariani C, Scarlato G. Pentazocine-induced neuromuscular syndrome: clinical, histochemical features in two cases and a tissue culture study of pentazocine-block myogenesis in human foetal muscle. **Basic and Applied Histochemistry** 1980; 24(3):193-202.
4. Meola G, Scarpini E, Silani V, Scarlato G. Manifesting carrier of x-linked Duchenne muscular dystrophy. **Journal of the Neurological Sciences** 1981;49(3):455-63.
5. Meola G, Scarpini E, Manfredi L, Mariani C, Scarlato G. Pentazocine-blocked myogenesis in human foetal muscle cultures. **Acta Neuropathologica Suppl (Berl)**. 1981; 7: 310-312.
6. Scarpini E, Meola G, Baron P, Moggio M, Silani V, Scarlato G. Morphological studies and quantitative assessment of the effect of chick embryo extract on monolayer cultures of normal human muscle. **Acta Neurologica (Napoli)** 1982;4(6):403-10.
7. Meola G, Scarpini E, Minetti C, Cordone G, Scarlato G. Clinical and histomorphological study of congenital myopathy with minimal lesions. **Minerva Pediatrica** 1982;34(21):891-6.
8. Meola G, Manfredi L, Scarpini E, Moggio M, Pellegrini G, Scarlato G. Cytochemical and ultrastructural studies of human foetal muscle in culture. **Acta Neurologica (Napoli)** 1983;5: 85-95.
9. Biral D, Damiani E, Margreth A, Scarpini E. Myosin subunit composition in human developing muscle. **Biochemistry Journal** 1984; 224(3): 923-31.
10. Dalla Libera L, Scarpini E, Manfredi L, Marini A. Urinary 3-methylhistidine output in newborn human infants. **Muscle & Nerve** 1984;7(6): 494-5.
11. Minetti C, Meola G, Scarpini E, Cordone G, Bado M, Scarlato G. The myopathy of congenital fiber type disproportion. **Minerva Pediatrica** 1984;36(4): 181-7.
12. Meola G, Scarpini E, Manfredi L, Velicogna M, Pellegrini G, Redi CA, Scarlato G. Infantile-acute acid maltase deficiency (Pompe's disease): studies of muscle cultures. **Basic and Applied Histochemistry** 1984;28(3):245-55.
13. Biral D, Damiani E, Margreth A, Scarpini E, Scarlato G. Slow myosin heavy chain isozyme in nemaline myopathy. **Neurology** 1985; 35(9): 1360-3.
14. Ross AH, Pleasure D, Sonnenfeld K, Atkinson B, Kreider B, Jackson DM, Taff I, Scarpini E, Lisak RP, Koprowski H. Expression of melanoma-associated antigens by normal and neurofibroma Schwann cells. **Cancer Research** 1986;46(11):5887-92.
15. Scarpini E, Meola G, Baron P, Beretta S, Velicogna M, Scarlato G. S-100 protein and laminin: immunocytochemical markers for human Schwann cells in vitro. **Experimental Neurology** 1986; 93(1):77-83.
16. Meola G, Scarpini E, Velicogna M, Scarlato G, Larizza L, Conti AF. Cytogenetic analysis and muscle differentiation in a girl with severe muscular dystrophy. **Journal of Neurology** 1986;233(3): 168-70.
17. Meola G, Scarpini E, Velicogna M, Mottura A, Baron PL, Beretta S, Scarlato G. Analysis of fibronectin expression during human muscle differentiation. **Basic and Applied Histochemistry** 1986;30(2):153-63.
18. Biral D, Damiani E, Scarpini E, Bet L, Bresolin N, Moggio M, Pellegrini G, Barbieri S, Scarlato G. Biochemical and immunologic studies in a case of congenital myopathy with unusual morphologic features. **Neurology** 1987;37(10):1658-62.
19. Scarpini E, Meola G, Baron PL, Beretta S, Velicogna M, Moggio M, Buscaglia M, Doronzo R, Scarlato G. Human Schwann cells: cytochemical, ultrastructural and immunological studies in vivo and in vitro. **Basic and Applied Histochemistry** 1987;31(1):33-42.
20. Scarpini E, Kreider BQ, Lisak RP, Pleasure DE. Establishment of Schwann cell cultures from adult rat peripheral nerves. **Experimental Neurology** 1988;102(2):167-76.
21. Scarpini E, Kreider BQ, Lisak RP, Meola G, Velicogna ME, Baron P, Beretta S, Buscaglia M, Ross AH, Scarlato G. Cultures of human Schwann cells isolated from fetal nerves. **Brain Research** 1988;440(2): 261-6.
22. Scarpini E, Ross AH, Rosen JL, Brown MJ, Rostami A, Koprowski H, Lisak RP. Expression of nerve growth factor receptor during human peripheral nerve development. **Developmental Biology** 1988; 125(2): 301-10.
23. Bresolin N, Monza G, Scarpini E, Scarlato G, Straneo G, Martinazzoli A, Beninca G, Cattoni C, De Candia R, Belloni G, et al. Treatment of anxiety with ketazolam in elderly patients. **Clinical Therapy** 1988;10(5):536-42.
24. Scarpini E, Baron PG, Bet L, Bottini G, Bresolin N, Meola G, Pezzoli G, Vallar G, Monza GC, Scarlato G. Low doses of ketazolam in anxiety: a double-blind, placebo-controlled study. **Neuropsychobiology** 1988;20(2):74-7.

25. Scarpini E, Beretta S, Ross AH, Moggio M, Jann S, Pleasure D, Scarlato G. Rapid quantitative immunohistochemical assessment of human peripheral neuropathies using a monoclonal antibody against nerve growth factor receptor. **Journal of Neurology** 1989;236(8):439-44.
26. Biral D, Scarpini E, Angelini C, Salviati G, Margreth A. Myosin heavy chain composition of muscle fibers in spinal muscular atrophy. **Muscle & Nerve** 1989;12(1):43-51.
27. Moggio M, Bresolin N, Scarpini E, Adobbati L, Prella A, Gallanti A, Bet L, Fortunato F, Pellegrini G, Scarlato G. Cytochrome c oxidase during human fetal development. **International Journal of Developmental Neuroscience**. 1989;7(1):5-14.
28. Scarpini E, Lisak RP, Beretta S, Velicogna M, Doronzo R, Moggio M, Jann S, Scarlato G. Quantitative assessment of class II molecules in normal and pathological nerves. Immunocytochemical studies in vivo and in tissue culture. **Brain** 1990; 113 (Pt 3): 659-75.
29. Vedeler CA, Scarpini E, Beretta S, Doronzo R, Matre R. The ontogenesis of Fc gamma receptors and complement receptors CR1 in human peripheral nerve. **Acta Neuropathologica** (Berl) 1990; 80(1): 35-40.
30. Scarpini E, Sacilotto G, Lazzarin A, Geremia L, Doronzo R, Scarlato G. Acute ataxia coincident with seroconversion for anti-HIV. **Journal of Neurology** 1991;238(6): 356-7.
31. Prella A, Chianese L, Moggio M, Gallanti A, Sciacco M, Checcarelli N, Comi G, Scarpini E, Bonilla E, Scarlato G. Appearance and localization of dystrophin in normal human fetal muscle. **International Journal of Developmental Neuroscience** 1991; 9(6):607-12.
32. Baron PL, Meola G, Scarpini E, Moggio M, Santilli I, Scarlato G. Lysosomotropic agents induce morphological and functional changes in human muscle cells in vitro. **European Journal of Basic and Applied Histochemistry** 1991;35(4):423-32.
33. Bottini G, Vallar G, Cappa S, Monza GC, Scarpini E, Baron P, Cheldi A, Scarlato G. Oxiracetam in dementia: a double-blind, placebo-controlled study. **Acta Neurologica Scandinavica** 1992;86(3): 237-41.
34. Gallanti A, Prella A, Chianese L, Barbieri S, Jann S, Schiaffino S, Comini A, Scarpini E, Pellegrini G, Moggio M, et al. Congenital myopathy with type 2A muscle fiber uniformity and smallness. **Neuropediatrics** 1992; 23(1):10-3.
35. Sciacco M, Scarpini E, Baron PL, Doronzo R, Moggio M, Passerini D, Scarlato G. Sural nerve immunoreactivity for nerve growth factor receptor in a case of localized hypertrophic neuropathy. **Acta Neuropathologica** (Berl). 1992;83(5):547-53.
36. Scarpini E, Doronzo R, Baron P, Moggio M, Basellini A, Scarlato G. Phenotypic and proliferative properties of Schwann cells from nerves of diabetic patients. **International Journal of Clinical and Pharmacological Research** 1992;12(5-6): 211-5.
37. Scarpini E, Bianchi R, Moggio M, Sciacco M, Fiori MG, Scarlato G. Decrease of nerve Na⁺,K⁽⁺⁾-ATPase activity in the pathogenesis of human diabetic neuropathy. **Journal of the Neurological Sciences** 1993;120: 159-67.
38. Conti AM, Malosio ML, Scarpini E, Di Giulio AM, Scarlato G, Mantegazza P, Gorio A. Myelin protein transcripts increase in experimental diabetic neuropathy. **Neuroscience Letters** 1993; 161:203-6.
39. Baron P, Constantin G, D'Andrea A, Ponzin D, Scarpini E, Scarlato G, Trinchieri G, Rossi F, Cassatella MA. Production of tumor necrosis factor and other proinflammatory cytokines by human mononuclear phagocytes stimulated with myelin P2 protein. **Proc Natl Acad Sci USA** 1993; 90:4414-8.
40. Baron P, Kamholz J, Scherer S, Honda H, Shy M, Scarpini E, Scarlato G, Pleasure D. Appearance of PLP mRNA in specific regions of the developing rat lumbosacral spinal cord as revealed by in situ hybridization. **Experimental Neurology** 1993;121:139-47.
41. Maggi S, Zucchetto M, Grigoletto F, Baldereschi M, Candelise L, Scarpini E, Scarlato G, Amaducci L. The Italian Longitudinal Study on Aging (ILSA): design and methods. **Aging** (Milano). 1994; 6(6):464-73.
42. Bet L, Moggio M, Comi GP, Mariani C, Prella A, Checcarelli N, Bordini A, Bresolin N, Scarpini E, Scarlato G. Multiple sclerosis and mitochondrial myopathy: an unusual combination of diseases. **Journal of Neurology** 1994;241(8): 511-6.
43. Baron P, Scarpini E, Meola G, Santilli I, Conti G, Pleasure D, Scarlato G. Expression of the low-affinity NGF receptor during human muscle development, regeneration, and in tissue culture. **Muscle & Nerve** 1994;17(3): 276-84.
44. Laudanna C, Constantin G, Baron P, Scarpini E, Scarlato G, Cabrini G, Dechecchi C, Rossi F, Cassatella MA, Berton G. Sulfatides trigger increase of cytosolic free calcium and enhanced expression of tumor necrosis factor-alpha and interleukin-8 mRNA in human neutrophils. Evidence for a role of L-selectin as a signaling molecule. **Journal of Biological Chemistry** 1994;269: 4021-6.
45. Conti G, Baron PL, Scarpini E, Vedeler C, Rostami A, Pleasure D, Scarlato G. Low-affinity nerve growth factor receptor expression in sciatic nerve during P2-peptide induced experimental allergic neuritis. **Neuroscience Letters** 1995;199:135-8.

46. Conti AM, Scarpini E, Malosio ML, Di Giulio AM, Baron P, Scarlato G, Mantegazza P, Gorio A. In situ hybridization study of myelin protein mRNA in rats with an experimental diabetic neuropathy. **Neuroscience Letters** 1996;207:65-9.
47. Scarpini E, Doneda P, Pizzul S, Chiodi P, Ramacci MT, Baron P, Conti G, Sacilotto G, Arduini A, Scarlato G. L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects. **Journal of the Peripheral Nervous System** 1996;1:157-63.
48. Scarpini E, Conti G, Chianese L, Baron P, Pizzul S, Basellini A, Livraghi S, Scarlato G. Induction of p75NGFR in human diabetic neuropathy. **Journal of the Neurological Sciences** 1996;135:55-62.
49. Baron P, Scarpini E, Pizzul S, Zotti F, Conti G, Pleasure D, Scarlato G. Immunocytochemical expression of human muscle cell p75 neurotrophin receptor is down-regulated by cyclic adenosine 3',5'-monophosphate. **Neuroscience Letters** 1997; 234(2-3): 79-82.
50. Conti G, Stoll G, Scarpini E, Baron PL, Bianchi R, Livraghi S, Scarlato G. p75 neurotrophin receptor induction and macrophage infiltration in peripheral nerve during experimental diabetic neuropathy: possible relevance on regeneration. **Experimental Neurology** 1997; 146(1): 206-211.
51. Scarpini E, Sacilotto G, Baron P, Cusini M, Scarlato G. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. **Journal of the Peripheral Nervous System** 1997;2:250-2.
52. Conti G, Scarpini E, Rostami A, Livraghi S, Baron PL, Pleasure D, Scarlato G. Schwann cell undergoes apoptosis during experimental allergic neuritis (EAN). **Journal of the Neurological Sciences** 1998;161:29-35.
53. Baron P, Constantini G, Meda L, Scarpini E, Scarlato G, Trinchieri G, Monastra G, Rossi F, Cassatella MA. Cultured human monocytes release proinflammatory cytokines in response to myelin basic protein. **Neuroscience Letters** 1998;252(3):151-4.
54. Rossi G, Macchi G, Porro M, Giaccone G, Bugiani M, Scarpini E, Scarlato G, Molini GE, Sasanelli F, Bugiani O, Tagliavini F. Fatal familial insomnia: genetic, neuropathologic, and biochemical study of a patient from a new Italian kindred. **Neurology** 1998;50(3): 688-92.
55. Galimberti D, Baron PL, Meda L, Prat E, Scarpini E, Delgado R, Catania A, Lipton JM, Scarlato G. α -MSH peptides inhibit production of nitric oxide and tumor necrosis factor- α by microglial cells activated with β -amyloid and interferon- γ . **Biochemical and Biophysical Research Communications** 1999;263:251-6.
56. Scarpini E, Conti GC, Bussini S, Clerici R, Siglienti I, Piccio L, De Pol A, Baron PL, Scarlato G. Human schwann cell proliferation and IL-6 production following TNF-alpha stimulation in vitro. **Ann N Y Acad Sci** 1999; 883:520-2.
57. Vedeler CA, Conti G, Fujioka T, Scarpini E, Rostami A. The expression of CD59 in experimental allergic neuritis. **Journal of the Neurological Sciences** 1999;165(2):154-9.
58. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. **Journal of Neuroimmunology** 1999; 93(1-2):45-52.
59. Cavanna B, Carpo M, Pedotti R, Scarpini E, Meucci N, Allaria S, Scarlato G, Nobile-Orazio E. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. **Journal of Neuroimmunology** 1999; 94(1-2):157-64.
60. Conti G, Scarpini E, Rostami A, Livraghi S, Clerici R, Piccio L, Siglienti I, Baron PL, Pleasure D, Scarlato G. Schwann cell apoptosis during cell-mediated demyelination. **Ann N Y Acad Sci** 1999 Sep 14;883:518-9.
61. Constantin G, Piccio L, Bussini S, Pizzuti A, Scarpini E, Baron P, Conti G, Pizzul S, Scarlato G. Induction of adhesion molecules on human schwann cells by proinflammatory cytokines, an immunofluorescence study. **Journal of the Neurological Sciences** 1999;170(2):124-30.
62. Prat E, Baron P, Meda L, Scarpini E, Galimberti D, Ardolino G, Catania A, Scarlato G. The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP-1) upon stimulation with β -amyloid protein. **Neuroscience Letters** 2000;283:177-180.
63. Bazzi P, Tancredi L, Scarpini E, Messina S, Sciacco M, Livraghi S, Vanoli M, Prella A, Scarlato G, Moggio M. Severe polyneuropathy in a patient with Churg-Strauss syndrome. **Journal of the Peripheral Nervous System** 2000;5(2):106-10.
64. Baron PL, Galimberti D, Meda L, Prat E, Scarpini E, Conti G, Moggio M, Prella A, Scarlato G. Synergistic effect of β -amyloid protein and Interferon- γ or nitric oxide production by C2C12 muscle cells. **Brain** 2000;123:374-9.
65. Baron P, Galimberti D, Meda L, Scarpini E, Conti G, Cogiamanian F, Scarlato G. Production of IL-6 by human myoblasts stimulated with A β : relevance in the pathogenesis of IBM. **Neurology** 2001;57:1561-5.
66. Clerici R, Conti G, Scarpini E, De Riz M, Baron PL, Scarlato G. Visual loss and enlarged extraocular muscles from metastatic signet ring carcinoma. **Journal of Neurology** 2001;248(4):336-8.
67. Rigamonti AE, Pincelli AI, Corrà B, Viarengo R, Bonomo SM, Galimberti D, Scacchi M, Scarpini E, Cavagnini F, Müller EE. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. **Journal of Endocrinology** 2002;175:R1-5.

68. Conti G, Scarpini E, Baron P, Livraghi S, Tiriticco M, Bianchi R, Vedeler C, Scarlato G. Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1 β and p75NTR. **Journal of the Neurological Sciences** 2002; 195(1):35-40.
69. Piccio L, Rossi B, Scarpini E, Laudanna C, Giagulli C, Issekutz AC, Vestweber D, Butcher EC, Constantin G. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. **Journal of Immunology** 2002; 168(4):1940-9.
70. Scarpini E, Galimberti D, Baron PL, Clerici R, Ronzoni M, Conti G, Scarlato G. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. **Journal of the Neurological Sciences** 2002;195:41-6.
71. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. **Lancet Neurology** 2003;2(9):539-47.
72. Micco A, Nobile-Orazio E, Baron P, Conti G, Napoli L, Serafini M, Scarlato G, Scarpini E. Severe chronic sensory-motor polyneuropathy: coexistence of 3 unrelated etiologies in a type 1 diabetic patient. A case report and review of the literature. **Journal of the Peripheral Nervous System** 2003;8(1):23-8.
73. Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, Ottoboni L, Ciabini D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G. CD8⁺ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. **Blood** 2003;101(12):4775-82.
74. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P, on behalf of the DIAR Group. Chemokines in CSF and serum from patients with different types of dementia. **Annals of Neurology** 2003;53:547-8.
75. Galimberti D, Bresolin N, Scarpini E. Chemokine network in Multiple Sclerosis: role in the pathogenesis and targeting for future treatments. **Expert Reviews Neurotherapeutics** 2004;4(3): 89-103.
76. Conti G, Rostami A, Scarpini E, Baron P, Galimberti D, Bresolin N, Contri M, Palumbo C, De Pol A. Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. **Experimental Neurology** 2004;187:350-8.
77. Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S, Tiriticco M, Mariani C, Forloni G, Pettenati C, Baron PL, Conti G, Bresolin N, Scarpini E. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. **Neurobiology of Aging** 2004;25(9):1169-73.
78. Galimberti D, Fenoglio C, Lovati C, Gatti A, Guidi I, Venturelli E, Cutter GR, Mariani C, Forloni G, Pettenati C, Baron PL, Conti G, Bresolin N, Scarpini E. *CCR2-64I* polymorphism and *CCR5 Δ 32* deletion in patients with Alzheimer's disease. **Journal of the Neurological Sciences** 2004;225:79-83.
79. Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, Tekin S, Lane R, Ferris S. Behavioral symptoms in mild cognitive impairment. **Neurology** 2004;62(7):1199-201.
80. Giagulli C, Scarpini E, Ottoboni L, Narumiya S, Butcher EC, Constantin G, Laudanna C. RhoA and zeta PKC control distinct modalities of LFA-1 activation by chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing. **Immunity** 2004;20(1):25-35.
81. Conti G, De Pol A, Scarpini E, Vaccina F, De Riz M, Baron P, Tiriticco M, Scarlato G. Interleukin-1 β and interferon- γ induce proliferation and apoptosis in cultured Schwann cells. **Journal of Neuroimmunology** 2002;124(1-2):29-35.
82. Scarpini E, Cogiamanian F. Alzheimer's disease: from molecular pathogenesis to innovative therapies. **Expert Reviews in Neurotherapeutics** 2003;3(5):619-30.
83. Guidi I, Galimberti D, Venturelli E, Lovati C, Del Bo R, Fenoglio C, Gatti A, Dominici R, Galbiati S, Virgilio R, Pomati S, Comi GP, Mariani C, Forloni G, Bresolin N, Scarpini E. Influence of the Glu298Asp polymorphism of *NOS3* on age at onset and homocysteine levels in AD patients. **Neurobiology of Aging** 2005;26(6): 789-94.
84. Del Bo R, Scarlato G, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, Virgilio R, Galimberti D, Galimberti G, Crimi M, Ferrarese C, Scarpini E, Bresolin N, Comi GP. VEGF gene variability is associated with increased risk of Alzheimer's disease. **Annals of Neurology** 2005;57: 373-8.
85. Furlan R, Rovaris M, Martinelli Boneschi F, Khademi M, Bergami A, Gironi M, Deleidi M, Agosta F, Franciotta D, Scarpini E, Uccelli A, Zaffaroni M, Kurne A, Comi G, Olsson T, Filippi M, Martino G. Immunological patterns identifying disease course and evolution in multiple sclerosis patients. **Journal of Neuroimmunology** 2005;165(1-2):192-200.
86. Venturelli E, Galimberti D, Lovati C, Fenoglio C, Mariani C, Forloni G, Bresolin N, Scarpini E. The *T-786C* *NOS3* polymorphism in Alzheimer's disease: association and influence on gene expression. **Neuroscience Letters** 2005;382:300-3.
87. Galimberti D, Fenoglio C, Clerici R, Comi C, De Riz M, Rottoli M, Piccio L, Ronzoni M, Venturelli E, Monaco F, Poloni M, Bresolin N, Scarpini E. E-selectin *A561C* and *G98T* polymorphisms influence susceptibility and progression of Multiple Sclerosis. **Journal of Neuroimmunology** 2005;165:201-5.

88. Galimberti D, Venturelli E, Gatti A, Lovati C, Fenoglio C, Mariani C, Forloni G, Bresolin N, Scarpini E. Association of neuronal Nitric Oxide Synthase C276T polymorphism with Alzheimer's disease. **Journal of Neurology** 2005; 252: 985-6.
89. Scalabrini D, Galimberti D, Fenoglio C, Comi C, De Riz M, Venturelli E, Castelli L, Piccio L, Ronzoni M, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with Multiple Sclerosis. **Neuroscience Letters** 2005;388: 149-52.
90. Piccio L, Rossi B, Colantonio L, Grenningloh R, Gho A, Ottoboni L, Homeister JW, Scarpini E, Martinello M, Laudanna C, D'Ambrosio D, Lowe JB, Constantin G. Efficient recruitment of lymphocytes in inflamed brain venules requires expression of cutaneous lymphocyte antigen and fucosyltransferase-VII. **Journal of Immunology** 2005;174(9):5805-13.
91. Bussini S, Meda L, Scarpini E, Clementi E, Conti G, Tiriticco M, Bresolin N, Baron P. Heparan sulphate proteoglycan induces the production of NO and TNF-alpha by murine microglia. **Immunity and Ageing** 2005;2:11.
92. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F, Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer's disease. **Archives of Neurology** 2005;62(11):1728-33.
93. Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, Scarpini E, Bresolin N, Wharton SB, Shaw PJ, Silani V. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. **Muscle & Nerve** 2005;32(4):541-4.
94. Annunziata P, Giorgio A, De Santi L, Zipoli V, Portaccio E, Amato MP, Clerici R, Scarpini E, Moscato G, Iudice A, Vacca G, Orefice G, Brescia Morra V, Maimone D. Absence of cerebrospinal fluid oligoclonal bands is associated with a delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. **Journal of the Neurological Sciences** 2006;244(1-2):97-102.
95. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron PL, Bresolin N, Scarpini E. Oxidative imbalance in patients with Mild Cognitive Impairment and Alzheimer's disease. **Neurobiology of Aging** 2006;27(2):262-9.
96. Del Bo, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, Galbiati S, Virgilio R, Galimberti D, Ferrarese C, Scarpini E, Bresolin N, Comi GP. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. **Neurobiology of Aging** 2006;27(5):770.
97. Scarpini E, Galimberti D, Guidi I, Bresolin N, Scheltens P. Progressive, isolated language disturbance: its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. **Journal of the Neurological Sciences** 2006;240:45-51.
98. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YAL, Bresolin N, Scarpini E. Intrathecal chemokine levels in Alzheimer's disease and Frontotemporal Lobar degeneration. **Neurology** 2006;66(1):146-7.
99. Fenoglio C, Galimberti D, Ban M, Maranian M, Scalabrini D, Venturelli E, Piccio L, De Riz M, Yeo T, Goris A, Gray J, Bresolin N, Scarpini E, Compston A, Sawcer S. SELPLG and SELP single nucleotide polymorphisms in multiple sclerosis. **Neuroscience Letters** 2006;394(2):92-6.
100. Saltini G, Dominici R, Lovati C, Cattaneo M, Michelini S, Malferrari G, Caprera A, Milanese L, Finazzi D, Bertora P, Scarpini E, Galimberti D, Venturelli E, Musicco M, Adorni F, Mariani C, Biunno I. A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. **Neuroscience Letters** 2006;398(1-2):53-8.
101. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. **Neurobiology of Aging** 2006;27:904-5.
102. Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corrà B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E. Serum MCP-1 levels are increased in Mild Cognitive Impairment and mild Alzheimer's disease. **Neurobiology of Aging** 2006;27:1763-8.
103. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E. Intrathecal chemokine synthesis in Mild Cognitive Impairment and Alzheimer's disease. **Archives of Neurology** 2006;63:538-43.
104. Scarpini E, Galimberti D, Bresolin N. Genetics and neurobiology of Frontotemporal Lobar Degeneration. **Neurological Sciences** 2006, 27 Suppl.1: S32-S34.
105. Giunta M, Rigamonti AE, Scarpini E, Galimberti D, Bonomo SM, Venturelli E, Müller EE, Cella SG. The leukocyte expression of CD36 is low in patients with Alzheimer's disease and Mild Cognitive Impairment. **Neurobiology of Aging** 2007, 28(4):515-8.

106. Venturelli E, Galimberti D, Fenoglio C, Lovati C, Finazzi D, Guidi I, Corrà B, Scalabrini D, Clerici F, Mariani C, Forloni G, Bresolin N, Scarpini E. Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. **Neuroscience Letters** 2006 ; 404: 217-21.
107. Pesaresi M, Batelli S, Prato F, Polito L, Lovati C, Scarpini E, Quadri P, Mariani C, Albani D, Forloni G. The urokinase-type plasminogen activator polymorphism PLAUI_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level. **Neurobiology of Disease** 2007;25(3):609-13.
108. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. **Lancet Neurology** 2007; 6(6):501-12.
109. Fenoglio C, Galimberti D, Piccio L, Scalabrini D, Panina P, Buonsanti C, Venturelli E, Lovati C, Baron P, Forloni G, Mariani C, Bresolin N, Scarpini E. Absence of polymorphisms in TREM-2 coding region in patients with early onset dementia. **Neuroscience letters** 2007;411:133-7.
110. Albani D, Batelli S, Prato F, Pesaresi M, Galimberti D, Scarpini E, Bruni A, Franceschi M, Piras MR, Confaloni A, Roiter I, Artuso V, Forloni G. Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. **Neurobiology of Aging** 2007, 28(11):1682-8.
111. Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. IP-10 haplotypes and Multiple Sclerosis: association and correlation with clinical course. **European Journal of Neurology** 2007;14:162-7.
112. Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D, Mariani C, Bresolin N, Scarpini E. IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. **European Journal of Neurology**, 2007;14:e3-e4.
113. Arosio B, Bergamaschini L, Galimberti L, La Porta C, Zanetti M, Calabresi C, Scarpini E, Annoni G, Vergani C. +10 T/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution. **Mechanisms of Ageing and Development** 2007;128(10):553-7.
114. Galimberti D, Scarpini E, Venturelli E, Strobel A, Herterich S, Fenoglio C, Guidi I, Scalabrini D, Cortini F, Bresolin N, Lesch KP, Reif A. Association of a NOS1 promoter repeat with Alzheimer's disease. **Neurobiology of Aging** 2008;29(9):1359-65.
115. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group (including Scarpini E). Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. **Lancet** 2008;371(9630):2085-92.
116. Maggi S, Noale M, Zambon A, Limongi F, Romanato G, Crepaldi G; ILSA Working Group (including Scarpini E). Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population: the Italian Longitudinal Study on Aging. **Atherosclerosis** 2008; 197(2): 877-82.
117. Ferrucci R, Mameli F, Guidi I, Mrakic-Sposta S, Vergari M, Marcegaglia S, Cogiamanian F, Barbieri S, Scarpini E, Priori A. Transcranial direct current stimulation improves recognition memory in Alzheimer disease. **Neurology** 2008; 71(7):493-8.
118. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group (including Scarpini E). The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. **Journal of Neurology** 2008;255(9):1315-23.
119. Poli M, Gatta LB, Lovati C, Mariani C, Galimberti D, Scarpini E, Biunno I, Musicco M, Dominici R, Albertini A, Finazzi D. Interaction between the APOE varepsilon4 allele and the APH-1b c+651T>G SNP in Alzheimer's disease. **Neurobiology of Aging** 2008; 29(10):1494-501.
120. Castelli L, Comi C, Chiocchetti A, Nicola S, Mesturini R, Giordano M, D'Alfonso S, Cerutti E, Galimberti D, Fenoglio C, Tesser F, Yagi J, Rojo JM, Perla F, Leone M, Scarpini E, Monaco F, Dianzani U. ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. **Journal of Neuroimmunology** 2007, 186(1-2):193-8.
121. Lovati C, Galimberti D, Pomati S, Capiluppi E, Dolci A, Scapellato L, Rosa S, Mailland E, Suardelli M, Vanotti A, Clerici F, Santarato D, Panteghini M, Scarpini E, Mariani C, Bertora P. Serum folate concentrations in patients with cortical and subcortical dementia. **Neuroscience Letters** 2007;420(3):213-6.
122. Del Bo R, Ghezzi S, Scarlato M, Albani D, Galimberti D, Lucca U, Tettamanti M, Scarpini E, Forloni G, Bresolin N, Comi GP. Role of VEGF gene variability in longevity: A lesson from the Italian population. **Neurobiology of Aging** 2008;29(12):1917-22.
123. Scalabrini D, Fenoglio C, Scarpini E, De Riz M, Comi C, Venturelli E, Cortini F, Piola M, Villa C, Naldi P, Monaco F, Bresolin N, Galimberti D. Candidate gene analysis of SPARCL1 gene in patients with Multiple Sclerosis. **Neuroscience Letters** 2007; 425: 173-6.

124. Galimberti D, Fenoglio C, Comi C, Scalabrini D, De Riz M, Leone M, Venturelli E, Cortini F, Piola M, Monaco F, Bresolin N, Scarpini E. MDC/CCL22 intrathecal levels in patients with multiple sclerosis. **Multiple Sclerosis** 2008; 14: 547-9.
125. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Scalabrini D, Baron P, Vergani C, Bresolin N, Scarpini E. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and Frontotemporal Lobar Degeneration. **Journal of Neurology** 2008 255(4):539-44.
126. Galimberti D, Scalabrini D, Fenoglio C, De Riz M, Comi C, Venturelli E, Cortini F, Piola M, Leone M, Dianzani U, D'Alfonso S, Monaco F, Bresolin N, Scarpini E. Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to multiple sclerosis. **Journal of the Neurological Sciences** 2008;267:86-90.
127. Venturelli E, Villa C, Scarpini E, Fenoglio C, Guidi I, Lovati C, Marcone A, Cortini F, Scalabrini D, Clerici F, Bresolin N, Mariani C, Cappa S, Galimberti D. Neuronal Nitric Oxide Synthase C276T polymorphism increases the risk for Frontotemporal Lobar Degeneration. **European Journal of Neurology** 2008;15:77-81.
128. Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? **Current Aging Science** 2008;1:30-41.
129. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco E, Ripellino P, Giuliani G, Montanari E, Clerico M; Italian Multiple Sclerosis Study Group (including Scarpini E). MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. **Journal of Neurology, Neurosurgery and Psychiatry** 2008; 79(6):646-51.
130. Cappellano G, Orilieri E, Comi C, Chiochetti A, Bocca S, Boggio E, Bernardone IS, Cometa A, Clementi R, Barizzone N, D'Alfonso S, Corrado L, Galimberti D, Scarpini E, Guerini FR, Caputo D, Paolicelli D, Trojano M, Figà-Talamanca L, Salvetti M, Perla F, Leone M, Monaco F, Dianzani U. Variations of the perforin gene in patients with multiple sclerosis. **Genes & Immunity** 2008, 9(5):438-44.
131. Reif A, Scarpini E, Venturelli E, Töpner T, Fenoglio C, Lesch KP, Galimberti D. The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia. **European Journal of Neurology** 2008;15(6):637-9.
132. Borroni B, Archetti S, Alberici A, Agosti C, Gennarelli M, Bigni B, Bonvicini C, Ferrari M, Bellelli G, Galimberti D, Scarpini E, Di Lorenzo D, Caimi L, Caltagirone C, Di Luca M, Padovani A. Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. **Neurogenetics** 2008;9(3):197-205.
133. Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. **Proceedings of the National Academy of Sciences USA** 2008;105(23):8050-4.
134. Drees-Werringloer U, Lambert J, Vingtdoux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Fokkett KJ, Campagne F, Marambaud P. A polymorphism in CALHM1 influences Ca²⁺ homeostasis, A β levels, and Alzheimer's disease risk. **Cell** 2008;133:1-13.
135. Benerini Gatta L, Vitali M, Zanola A, Venturelli E, Fenoglio C, Galimberti D, Scarpini E, Finazzi D. Polymorphisms in the LOC387715/ARMS2 Putative Gene and the Risk for Alzheimer's Disease. **Dement Geriatr Cogn Disord** 2008;26(2):169-74.
136. Borroni B, Ghezzi S, Agosti C, Archetti S, Fenoglio C, Galimberti D, Scarpini E, Di Luca M, Bresolin N, Comi GP, Padovani A, Del Bo R. Preliminary Evidence that VEGF Genetic Variability Confers Susceptibility to Frontotemporal Lobar Degeneration. **Rejuvenation Research** 2008;11(4):773-80.
137. Cortini F, Fenoglio C, Guidi I, Venturelli E, Pomati S, Marcone A, Scalabrini D, Villa C, Clerici F, Dalla Valle E, Mariani C, Cappa S, Bresolin N, Scarpini E, Galimberti D. Novel exon 1 progranulin gene variant in Alzheimer's disease. **European Journal of Neurology** 2008;15:1111-7.
138. Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J 2nd, Naismith RT, Panina-Bordignon P, Passini N, Galimberti D, Scarpini E, Colonna M, Cross AH. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. **Brain** 2008; 131(Pt 11):3081-91.
139. Albani D, Prato F, Fenoglio C, Batelli S, Dusi S, De Mauro S, Polito L, Lovati C, Galimberti D, Mariani C, Scarpini E, Forloni G. Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. **Journal of Human Genetics** 2008 2008;53(11-12):1029-33.
140. Galimberti D, Scarpini E. New Perspectives for the Treatment of Alzheimer's Disease. **The Open Geriatric Medicine Journal** 2008;1:33-42.
141. Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Ghidoni R, Cortini F, Scalabrini D, Gallone S, Rainero I, Mandelli A, Restelli I, Binetti G, Cappa S, Mariani C, Giordana MT, Bresolin N, Scarpini E, Galimberti D. The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. **European Journal of Neurology** 2009;16:37-42.

142. Hansmannel F, Lendon C, Pasquier F, Dumont J, Hannequin D, Chapuis J, Laumet G, Ayral AM, Galimberti D, Scarpini E, Campion D, Amouyel P, Lambert JC. Is the ornithine transcarbamylase gene a genetic determinant of Alzheimer's disease? **Neuroscience Letters** 2009;449(1):76-80.
143. Fenoglio C, Scalabrini D, Piccio L, De Riz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks B, Rinker J, Cross AH, Bresolin N, Scarpini E, Galimberti D. Candidate gene analysis of selectin cluster in patients with multiple sclerosis. **Journal of Neurology** 2009 256:832–3.
144. Albani D, Batelli S, Polito L, Prato F, Pesaresi M, Gajo GB, De Angeli S, Zanardo A, Galimberti D, Scarpini E, Gallucci M, Forloni G. Interleukin-6 plasma level increases with age in an Italian elderly population ("The Treviso Longeva"-Trelong-study) with a sex-specific contribution of rs1800795 polymorphism. **Age (Dordr)** 2009;31(2):155-62.
145. Villa C, Venturelli E, Fenoglio C, Clerici F, Marcone A, Benussi L, Guidoni R, Gallone S, Cortini F, Scalabrini D, Serpente M, Binetti G, Cappa S, Mariani C, Rainero I, Bresolin N, Scarpini E, Galimberti D. CCL8/MCP-2 association analysis in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. **Journal of Neurology** 2009;256:1379–81.
146. Galimberti D, Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Benussi L, Cortini F, Scalabrini D, Perini L, Restelli I, Binetti G, Cappa S, Mariani C, Bresolin N, Scarpini E. MCP-1 A-2518G polymorphism: effect on susceptibility for Frontotemporal Lobar Degeneration and on cerebrospinal fluid MCP-1 levels. **Journal of Alzheimer Disease** 2009;17:125-33.
147. Villa C, Venturelli E, Fenoglio C, Clerici F, Marcone A, Benussi L, Gallone S, Scalabrini D, Cortini F, Serpente M, Martinelli Boneschi F, Cappa S, Binetti G, Mariani C, Rainero I, Giordana MT, Bresolin N, Scarpini E, Galimberti D. *DCUN1D1* is a risk factor for Frontotemporal Lobar Degeneration. **European Journal of Neurology** 2009;16:870–3.
148. Fenoglio C, Galimberti D, Cortini F, Kauwe JSK, Cruchaga C, Venturelli E, Villa C, Serpente M, Scalabrini D, Mayo K, Piccio LM, , Clerici F, Albani D, Mariani C, Forloni G, Bresolin N, Goate AM, Scarpini E. rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. **Journal of Alzheimer Disease**, 2009;18(3):603-12.
149. Albani D, Vittori A, Batelli S, Polito L, De Mauro S, Galimberti D, Scarpini E, Lovati C, Mariani C, Forloni G. The serotonin transporter gene polymorphic element 5-HTTLPR increases sporadic parkinson's disease risk in Italy. **European Neurology**, 2009;62(2):120-3.
150. Goumidi L, Flamant F, Lendon C, Galimberti D, Pasquier F, Scarpini E, Hannequin D, Campion D, Amouyel P, Lambert JC, Meirhaeghe A. Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer's disease. **Neurobiology of Aging** 2011; 32(4): 624-30.
151. Scarpini E, Galimberti D. Alzheimer's disease: from pathogenesis to novel therapeutic approaches. **Therapy** 2009; 6(2): 259-77.
152. Del Bo R, Corti S, Santoro D, Ghione I, Fenoglio C, Ghezzi S, Ranieri M, Galimberti D, Mancuso M, Siciliano G, Briani C, Murri L, Scarpini E, Schymick JC, Traynor BJ, Bresolin N, Comi GP. No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. **Neurobiology of Aging** 2011;32(6):1157-8.
153. Albani D, Prato F, Tettamanti M, Lovati C, Galimberti D, Restelli I, Mariani C, Quadri PL, Scarpini E, Lucca U, Forloni G. The Serotonin Transporter Promoter Polymorphic Region is not a Risk Factor for Alzheimer's Disease Related Behavioral Disturbances. **Journal of Alzheimer's Disease** 2009;18(1):125-30.
154. Carecchio M, Fenoglio C, De Riz M, Guidi I, Comi C, Cortini F, Venturelli E, Restelli I, Cantoni C, Bresolin N, Monaco F, Scarpini E, Galimberti D. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnesic Mild Cognitive Impairment converted to Alzheimer's disease. **Journal of the Neurological Sciences** 2009;287(1-2): 291-3.
155. Farina E, Baglio F, Caffarra P, Magnani G, Scarpini E, Appollonio I, Bascelli C, Cheldi A, Nemni R, Franceschi M; Italian Group for Lewy Body Dementia and Dementias Associated to Parkinsonism, Messa G, Mantovani F, Bellotti M, Olivetto F, Alberoni M, Isella V, Regazzoni R, Schiatti E, Vismara C, Falautano M, Barbieri A, Restelli I, Fetoni V, Donato M, Zuffi M, Castiglioni S. Frequency and clinical features of Lewy body dementia in Italian memory clinics. **Acta Biomedica** 2009;80(1):57-64.
156. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group (including Scarpini E). Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. **Multiple Sclerosis** 2009;15(7):779-88.
157. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C; Memantine Lombardy Study Group (including Scarpini E). Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study. **Drugs & Aging** 2009;26(4):321-32.
158. Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory

- Treatment of Early-onset MS) Group (including [Scarpini E](#)). Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. **Neurological Sciences** 2009;30(3):193-9.
159. Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group (including [Scarpini E](#)). Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b. **Expert Opinion Biology & Therapy** 2009;9(4):387-97.
 160. De Stefano N, Filippi M, Confavreux C, Vermersch P, Simu M, Sindic C, Hupperts R, Bajenaru O, Edan G, Grimaldi L, Marginean I, Medaer R, Orefice G, Pascu I, Pelletier J, Sanders E, [Scarpini E](#), Mancardi GL. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. **Multiple Sclerosis** 2009;15(2):238-43.
 161. Del Bo R, Ghezzi S, [Scarpini E](#), Bresolin N, Comi GP. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. **Journal of the Neurological Sciences** 2009;283(1-2):66-8.
 162. Benussi L, Ghidoni R, Galimberti D, Boccardi M, Fenoglio C, [Scarpini E](#), Frisoni GB, Binetti G. The CST3 B haplotype is associated with frontotemporal lobar degeneration. **European Journal of Neurology** 2010;17(1):143-6.
 163. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, the European Alzheimer's Disease Initiative Investigators (including [Scarpini E](#)), de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. **Nature Genetics** 2009;41(10):1094-9.
 164. Gallone S, Giordana MT, [Scarpini E](#), Rainero I, Rubino E, Fenoglio P, Galimberti D, Grifoni S, Venturelli E, Acutis PL, Peletto S, Maniaci MG, Ferrero P, Zotta M, Pinessi L. Absence of TARDBP Gene Mutations in an Italian Series of Patients with Frontotemporal Lobar Degeneration. **Dementia and Geriatric Cognitive Disorders** 2009;28(3):239-43.
 165. Vitali M, Venturelli E, Galimberti D, Benerini Gatta L, [Scarpini E](#), Finazzi D. Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease. **Journal of Neural Transmission** 2009; 116(12):1635-41.
 166. Braghin E, Galimberti D, [Scarpini E](#), Bresolin N, Baron P. Alpha1-antichymotrypsin induces TNF-alpha production and NF-kappaB activation in the murine N9 microglial cell line. **Neuroscience Letters** 2009; 467(1): 40-2.
 167. Laumet G, Petitprez V, Sillaire A, Ayrat AM, Hansmanel F, Chapuis J, Hannequin D, Pasquier F, [Scarpini E](#), Galimberti D, Lendon C, Campion D, Amouyel P, Lambert JC. A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. **Neuroscience Letters** 2010;468(1):1-2.
 168. Bergamaschi L, Leone MA, Fasano ME, Guerini FR, Ferrante D, Bolognesi E, Barizzzone N, Corrado L, Naldi P, Agliardi C, Dametto E, Salvetti M, Visconti A, Galimberti D, [Scarpini E](#), Vercellino M, Bergamaschi R, Monaco F, Caputo D, Momigliano-Richiardi P, D'Alfonso S. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. **Genes & Immunity** 2010;11(2):173-80.
 169. Galimberti D, [Scarpini E](#). Treatment of Alzheimer's Disease: symptomatic and disease-modifying approaches. **Current Aging Science** 2010; 3(1): 46-56.
 170. Di Maria E, Cammarata S, Parodi MI, Borghi R, Benussi L, Galli M, Galimberti D, Ghidoni R, Gonella D, Novello C, Pollero V, Perroni L, Odetti P, [Scarpini E](#), Binetti G, Tabaton M. The H1 Haplotype of the Tau Gene (MAPT) is Associated with Mild Cognitive Impairment. **Journal of Alzheimer's Disease** 2010; 19(3): 909-14.
 171. Villa C, Venturelli E, Fenoglio C, De Riz M, Scalabrini D, Cortini F, Serpente M, Cantoni C, Bresolin N, [Scarpini E](#), Galimberti D. Candidate gene analysis of semaphorins in patients with Alzheimer's disease. **Neurological Sciences** 2010; 31:169-73.
 172. De Riz M, Galimberti D, Fenoglio C, Piccio LM, Scalabrini D, Venturelli E, Pietroboni A, Piola M, Naismith RT, Parks BJ, Fumagalli G, Bresolin N, Cross AH, [Scarpini E](#). Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. **Neuroscience Letters** 2010;469:234-6.
 173. Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, Cappellano G, Monaco F, [Scarpini E](#), Dianzani U. Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline. **Journal of Alzheimer's Disease** 2010;19(4):1143-8.
 174. Galimberti D, Fenoglio C, Cortini F, Serpente M, Venturelli E, Villa C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Scalabrini D, Restelli I, Boneschi FM, Cappa S, Binetti G, Mariani C, Rainero I,

- Giordana MT, Bresolin N, Scarpini E. GRN variability contributes to sporadic frontotemporal lobar degeneration. **Journal of Alzheimer's Disease** 2010;19(1):171-7.
175. Cantoni C, Fenoglio C, Cortini F, Venturelli E, Villa C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Scalabrini D, Franceschi M, Cappa S, Binetti G, Mariani C, Rainero I, Giordana MT, Bresolin N, Scarpini E, Galimberti D. FUS/TLS Genetic Variability in Sporadic Frontotemporal Lobar Degeneration. **Journal of Alzheimer's Disease** 2010;19(4):1317-22.
 176. Martinelli-Boneschi F, Esposito F, Scalabrini D, Fenoglio C, Rodegher ME, Brambilla P, Colombo B, Ghezzi A, Capra R, Collimedaglia L, Coniglio G, De Riz M, Serpente M, Cantoni C, Scarpini E, Martinelli V, Galimberti D, Comi G. Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. **European Journal of Neurology** 2010;17:740-5.
 177. Mishto M, Bellavista E, Ligorio C, Textoris-Taube K, Santoro A, Giordano M, D'Alfonso S, Listì F, Nacmias B, Cellini E, Leone M, Grimaldi LM, Fenoglio C, Esposito F, Martinelli-Boneschi F, Galimberti D, Scarpini E, Seifert U, Amato MP, Caruso C, Foschini MP, Kloetzel PM, Franceschi C. Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. **PLoS One** 2010;5(2):e9287.
 178. Lovati C, Galimberti D, Albani D, Bertora P, Venturelli E, Cislighi G, Guidi I, Fenoglio C, Cortini F, Clerici F, Finazzi D, Forloni G, Scarpini E, Mariani C. APOE ϵ 2 and ϵ 4 influence the susceptibility for Alzheimer's disease but not other dementias. **International Journal of Molecular Epidemiological Genetics** 2010;1(3):193-200.
 179. Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group (including Scarpini E). Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. **Multiple Sclerosis** 2010; 16(11):1360-6.
 180. Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. **Brain Research** 2010;28;1333:64-71.
 181. Fenoglio C, Scalabrini D, Esposito F, Comi C, Cavalla P, De Riz M, Martinelli V, Piccio LM, Venturelli E, Fumagalli G, Capra R, Collimedaglia L, Ghezzi A, Rodegher ME, Vercellino M, Leone M, Giordana MT, Bresolin N, Monaco F, Comi G, Scarpini E, Martinelli-Boneschi F, Galimberti D. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. **Genes & Immunity** 2010;11(6):497-503.
 182. Lescai F, Pirazzini C, D'Agostino G, Santoro A, Ghidoni R, Benussi L, Galimberti D, Federica E, Marchegiani F, Cardelli M, Olivieri F, Nacmias B, Sorbi S, Bagnoli S, Tagliavini F, Albani D, Boneschi FM, Binetti G, Forloni G, Quadri P, Scarpini E, Franceschi C. Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. **Journal of Alzheimer's Disease** 2010;21(2):385-8.
 183. Galimberti D, Scarpini E. Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. **International Journal of Clinical and Experimental Medicine** 2010;3(2):129-43.
 184. Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Scalabrini D, Cortini F, Fumagalli G, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration? **Neuroscience Letters** 2010;482:240-4.
 185. Lambert JC, Sleegers K, González-Pérez A, Ingelsson M, Beecham GW, Hiltunen M, Combarros O, Bullido MJ, Brouwers N, Bettens K, Berr C, Pasquier F, Richard F, Dekosky ST, Hannequin D, Haines JL, Tognoni G, Fiévet N, Dartigues JF, Tzourio C, Engelborghs S, Arosio B, Coto E, De Deyn P, Del Zompo M, Mateo I, Boada M, Antunez C, Lopez-Arrieta J, Epelbaum J, Schjeide BM, Frank-Garcia A, Giedraitis V, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Delepine M, Zelenika D, Lathrop M, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Valdivieso F, Vepsäläinen S, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Hanon O, Piccardi P, Annoni G, Mann D, Marambaud P, Seripa D, Galimberti D, Tanzi RE, Bertram L, Lendon C, Lannfelt L, Licastro F, Campion D, Pericak-Vance MA, Soininen H, Van Broeckhoven C, Alperovitch A, Ruiz A, Kamboh MI, Amouyel P. The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. **Journal of Alzheimer's Disease** 2010;22(1):247-55.
 186. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group (including Scarpini E). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. **New England Journal of Medicine** 2010;362(5):402-15.
 187. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group (including Scarpini E). Effects of

- immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. **Multiple Sclerosis** 2010;16(1):68-77.
188. Borroni B, Bonvicini C, Galimberti D, Tremolizzo L, Papetti A, Archetti S, Turla M, Alberici A, Agosti C, Premi E, Appollonio I, Rainero I, Ferrarese C, Gennarelli M, Scarpini E, Padovani A. Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. **Neurobiology of Aging** 2011; 32(3): 555.e1-8.
 189. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group (including Scarpini E). Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. **Neurology** 2011; 77(21): 1887-95.
 190. Cortini F, Fenoglio C, Venturelli E, Villa C, Clerici F, Serpente M, Cantoni C, Fumagalli G, Mariani C, Bresolin N, Scarpini E, Galimberti D. Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimer's disease. **Journal of Neurology** 2011; 258: 704-5.
 191. Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Cortini F, Serpente M, Cantoni C, Fumagalli G, Ridolfi E, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. BAG1 is a Protective Factor for Sporadic Frontotemporal Lobar Degeneration but not for Alzheimer's Disease. **Journal of Alzheimer's Disease** 2011; 23(4):701-7.
 192. Galimberti D, Scarpini E. Inflammation and oxidative damage in Alzheimer's disease: friend or foe? **Frontiers in Biosciences (Schol Ed)** 2011;3:252-66.
 193. Lambert JC, Zelenika D, Hiltunen M, Chouraki V, Combarros O, Bullido MJ, Tognoni G, Fiévet N, Boland A, Arosio B, Coto E, Zompo MD, Mateo I, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Delepine M, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Valdivieso F, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F, Lathrop M, Soininen H, Amouyel P. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. **Neurobiology of Aging** 2011; 32(4): 756.e11-5.
 194. Galimberti D, Scarpini E. Alzheimer's Disease: From Pathogenesis to Disease-Modifying Approaches. **CNS Neurological Disorders Drug Targets** 2011; 10(2): 163-74.
 195. Pietroboni AM, Fumagalli GG, Ghezzi L, Fenoglio C, Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P, Carecchio M, Bassi M, Bresolin N, Galbiati D, Galimberti D, Scarpini E. Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. **Journal of Alzheimer's Disease** 2011; 24(2): 253-9.
 196. Lescai F, Chiamanti AM, Codemo A, Pirazzini C, D'Agostino G, Ruaro C, Ghidoni R, Benussi L, Galimberti D, Esposito F, Marchegiani F, Cardelli M, Olivieri F, Nacmias B, Sorbi S, Tagliavini F, Albani D, Boneschi FM, Binetti G, Santoro A, Forloni G, Scarpini E, Crepaldi G, Gabelli C, Franceschi C. An APOE Haplotype Associated with Decreased $\epsilon 4$ Expression Increases the Risk of Late Onset Alzheimer's Disease. **Journal of Alzheimer's Disease** 2011; 24(2): 235-45.
 197. Bollati V, Galimberti D, Pergoli L, Valle ED, Barretta F, Cortini F, Scarpini E, Bertazzi PA, Baccarelli A. DNA methylation in Repetitive Elements and Alzheimer disease. **Brain Behavior and Immunity** 2011; 25(6): 1078-83.
 198. Ragheb S, Li Y, Simon K, Vanhaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. **Multiple Sclerosis** 2011; 17(7): 819-29.
 199. Bergamaschi L, Ban M, Barizzzone N, Leone M, Ferrante D, Fasano ME, Guerini FR, Corrado L, Naldi P, Dametto E, Agliardi C, Salvetti M, Mechelli R, Galimberti D, Scarpini E, Cavalla P, Bargiggia V, Caputo D, Cordera S, Monaco F, Momigliano-Richiardi P, D'Alfonso S. Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. **Journal of Medical Genetics** 2011;48(7):485-92.
 200. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Gallacher J, Hüll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC; the Alzheimer's Disease Neuroimaging Initiative, van Duijn CM, Breteler MM, Ikram MA, Destefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S; CHARGE consortium, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M; EADI consortium, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S,

- Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snædal J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. **Nature Genetics** 2011;43(5):429-35.
201. Grünblatt E, Reif A, Jungwirth S, Galimberti D, Weber H, Scarpini E, Sauer C, Wichart I, Rainer MK, Huber K, Danielczyk W, Tragl KH, Deckert J, Fischer P, Riederer P. Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: The VITA and Milano studies. **Journal of Psychiatric Research** 2011;45(9):1250-6.
 202. Galimberti D, Macmurray J, Scalabrini D, Fenoglio C, De Riz M, Comi C, Comings D, Cortini F, Villa C, Serpente M, Cantoni C, Ridolfi E, Fardipoor MH, Leone M, Monaco F, Bresolin N, Scarpini E. GSK3 β genetic variability in patients with Multiple Sclerosis. **Neuroscience Letters** 2011;497(1):46-8.
 203. Villa C, Fenoglio C, De Riz M, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Cortini F, Serpente M, Cantoni C, Fumagalli G, Boneschi FM, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. Role of hnRNP-A1 and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. **Rejuvenation Research** 2011;14(3):275-81.
 204. Dominici R, Ronchi M, Galimberti D, Scarpini E, Finazzi D. Lack of Association between the GPR3 Gene and the Risk for Alzheimer's Disease. **International Journal of Alzheimer's Disease** 2011;2011:576143.
 205. Villa C, Ghezzi L, Pietroboni AM, Fenoglio C, Cortini F, Serpente M, Cantoni C, Ridolfi E, Marcone A, Benussi L, Ghidoni R, Jacini F, Arighi A, Fumagalli GG, Mandelli A, Binetti G, Cappa S, Bresolin N, Scarpini E, Galimberti D. A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. **Journal of Alzheimer's Disease** 2011;26:19-26.
 206. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, Pasquier F, Dubois B, Tognoni G, Fiévet N, Brouwers N, Bettens K, Arosio B, Coto E, Del Zompo M, Mateo I, Epelbaum J, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Valdivieso F, Vepsäläinen S, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Hanon O, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F, Soininen H, Dartigues JF, Kamboh MI, Van Broeckhoven C, Lambert JC, Amouyel P, Campion D. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. **Molecular Psychiatry**. 2011;16(9):903-7.
 207. Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group (including Scarpini E). Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β -1a in the COGNitive Impairment in Multiple Sclerosis (COGIMUS) study. **BMC Neurology** 2011;11:125.
 208. Bossu P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, Scarpini E, Spalletta G, Caltagirone C, Padovani A, Borroni B. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. **Journal of Neuroinflammation** 2011;8(1):65.
 209. Polito L, Prato F, Rodilossi S, Ateri E, Galimberti D, Scarpini E, Clerici F, Mariani C, Forloni G, Albani D. A novel study and meta-analysis of the genetic variation of the serotonin transporter promoter in the Italian population do not support a large effect on Alzheimer's disease risk. **International Journal of Alzheimer's Disease** 2011;2011:312341.
 210. Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer's disease. **Therapeutic Advances in Neurological Disorders** 2011;4:203-16.
 211. Galimberti D, Scarpini E. Progress in Alzheimer's disease. **Journal of Neurology** 2012;259(2): 201-11.
 212. Serpente M, Fenoglio C, Villa C, Cortini F, Cantoni C, Ridolfi E, Clerici F, Marcone A, Benussi L, Ghidoni R, Boneschi FM, Gallone S, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. Role of OLR1 and Its Regulating hsa-miR369-3p in Alzheimer's Disease: Genetics and Expression Analysis. **Journal of Alzheimer's Disease** 2011; 26:787-93.
 213. Cagliani R, Fumagalli M, Guerini FR, Riva S, Galimberti D, Comi GP, Agliardi C, Scarpini E, Pozzoli U, Forni D, Caputo D, Asselta R, Biasin M, Paraboschi EM, Bresolin N, Clerici M, Sironi M. Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. **Human Genetics** 2012;131(1):87-97.
 214. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O,

- Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, [Scarpini E](#), Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. **Alzheimers & Dementia** 2011;7(4):386-395.e6.
215. Rainero I, Rubino E, Negro E, Gallone S, Galimberti D, Gentile S, [Scarpini E](#), Pinessi L. Heterosexual Pedophilia in a Frontotemporal Dementia Patient with a Mutation in the Progranulin Gene. **Biological Psychiatry** 2011;70(9):e43-4.
 216. Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, Villa C, Comi C, Monaco F, Mellesi L, Valzelli S, Bresolin N, Galimberti D, [Scarpini E](#). Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. **Neuroscience Letters** 2011;504(1):9-12.
 217. Cerami C, Marcone A, Galimberti D, Villa C, [Scarpini E](#), Cappa SF. From Genotype to Phenotype: Two Cases of Genetic Frontotemporal Lobar Degeneration with Premorbid Bipolar Disorder. **Journal of Alzheimer's Disease** 2011;27:791-7.
 218. Carecchio M, Fenoglio C, Cortini F, Comi C, Benussi L, Ghidoni R, Borroni B, De Riz M, Serpente M, Cantoni C, Franceschi M, Albertini V, Monaco F, Rainero I, Binetti G, Padovani A, Bresolin N, [Scarpini E](#), Galimberti D. Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers. **Journal of Alzheimer's Disease** 2011;27:781-90.
 219. Mosca L, Marazzi R, Ciccone A, Santilli I, Bersano A, Sansone V, Grosso E, Mandrile G, Giachino DF, Adobbati L, Corengia E, Agostoni E, Fiumani A, Gallone S, [Scarpini E](#), Guidotti M, Sterzi R, Ajmone C, Marocchi A, Penco S. NOTCH3 gene mutations in subjects clinically suspected of CADASIL. **Journal of the Neurological Sciences** 2011;307(1-2):144-8.
 220. [Scarpini E](#), Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B. Cessation versus Continuation of Galantamine Treatment after 12 Months of Therapy in Patients with Alzheimer's Disease: A Randomized, Double Blind, Placebo Controlled Withdrawal Trial. **Journal of Alzheimer's Disease** 2011;26(2):211-20.
 221. Rossi B, Zenaro E, Angiari S, Ottoboni L, Bach S, Piccio L, Pietronigro EC, [Scarpini E](#), Fusco M, Leon A, Constantin G. Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism. **Journal of Neuroimmunology** 2011;233(1-2):97-105.
 222. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group (including [Scarpini E](#)). Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. **Lancet Neurology** 2011;10:520-9.
 223. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group (including [Scarpini E](#)). Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in Multiple Sclerosis) study. **Multiple Sclerosis** 2011;17(8):991-1001.
 224. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group (including [Scarpini E](#)). Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. **Annals of Neurology** 2011;69(1):75-82.
 225. Annunziata P, De Santi L, Di Rezze S, Millefiorini E, Capello E, Mancardi G, De Riz M, [Scarpini E](#), Vecchio R, Patti F. Clinical features of Sjogren's syndrome in patients with multiple sclerosis. **Acta Neurologica Scandinavica** 2011;124(2):109-14.
 226. Caso F, Villa C, Fenoglio C, Santangelo R, Agosta F, Coppi E, Falautano M, Comi G, Filippi M, [Scarpini E](#), Magnani G, Galimberti D. The GRN Cys157LysfsX97 Mutation is Associated with Nonfluent Variant of Primary Progressive Aphasia Clinical Phenotype. **Journal of Alzheimer's Disease** 2012;28:759-63.
 227. Martinelli Boneschi F, Fenoglio C, Brambilla P, Sorosina M, Giacalone G, Esposito F, Serpente M, Cantoni C, Ridolfi E, Rodegher M, Moiola L, Colombo B, De Riz M, Martinelli V, [Scarpini E](#), Comi G, Galimberti D. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. **Neuroscience Letters** 2012;508(1):4-8.
 228. Ghidoni R, Stoppani E, Rossi G, Piccoli E, Albertini V, Paterlini A, Glionna M, Pegoiani E, Agnati LF, Fenoglio C, [Scarpini E](#), Galimberti D, Morbin M, Tagliavini F, Binetti G, Benussi L. Optimal Plasma Progranulin Cutoff Value for Predicting Null Progranulin Mutations in Neurodegenerative Diseases: A Multicenter Italian Study. **Neurodegenerative Diseases** 2012; 9(3):121-7.

229. Ghezzi L, Arighi A, Pietroboni AM, Jacini F, Fumagalli GG, Esposito A, Bresolin N, Galimberti D, Scarpini E. Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. **Journal of Neurology** 2012; 259(7):1470-1.
230. Musicco M, Padovani A, Sorbi S, Scarpini E, Caffarra P, Cappa S, Clerici F, Tabaton M, Caltagirone C, Bonavita V, Bruni AC, Bruno G, Federico A, Ferrarese C, Marra C, Nacmias B, Parnetti L, Pettenati C, Sorrentino G, Tagliavini F, Mariani C. Position paper of the Italian Society for the study of Dementias (SINDEM) on the proposal of a new lexicon on Alzheimer disease. **Neurological Sciences** 2012;33(1):201-8.
231. Guerini FR, Cagliani R, Forni D, Agliardi C, Caputo D, Cassinotti A, Galimberti D, Fenoglio C, Biasin M, Asselta R, Scarpini E, Comi GP, Bresolin N, Clerici M, Sironi M. A Functional Variant in ERAP1 Predisposes to Multiple Sclerosis. **PLoS One** 2012;7(1):e29931.
232. Galimberti D, Scarpini E. Behavioral Genetics of Neurodegenerative Disorders. **Current Topics in Behavioral Neurosciences** 2012;12:615-31.
233. Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Mastronardi L, Romualdi P, Candeletti S, Gussago C, Galimberti D, Scarpini E, Dell'Osso B, Altamura C, Maccarrone M, Bergamaschini L, D'Addario C, Mari D. Pin1 Contribution to Alzheimer's Disease: Transcriptional and Epigenetic Mechanisms in Patients with Late-Onset Alzheimer's Disease. **Neurodegenerative Diseases** 2012; 10(1-4):207-11.
234. Cagliani R, Guerini FR, Fumagalli M, Riva S, Agliardi C, Galimberti D, Pozzoli U, Goris A, Dubois B, Fenoglio C, Forni D, Sanna S, Zara I, Pitzalis M, Zoladzewska M, Cucca F, Marini F, Comi GP, Scarpini E, Bresolin N, Clerici M, Sironi M. A trans-specific polymorphism in ZC3HAV1 is maintained by long-standing balancing selection and may confer susceptibility to multiple sclerosis. **Molecular Biology and Evolution** 2012; 29(6):1599-613.
235. Di Maria E, Giorgio E, Uliana V, Bonvicini C, Faravelli F, Cammarata S, Galimberti D, Scarpini E, Zanetti O, Gennarelli M, Tabaton M. Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. **Journal of Alzheimer's Disease** 2012; 29(3):699-705.
236. D'Addario C, Dell'osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, Galimberti D, Fenoglio C, Cortini F, Scarpini E, Arosio B, Di Francesco A, Di Benedetto M, Romualdi P, Candeletti S, Mari D, Bergamaschini L, Bresolin N, Maccarrone M, Altamura AC. Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII. **Neuropsychopharmacology** 2012;37(7):1647-55.
237. Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, Kamatani Y, Sleegers K, Ikram MA, Hiltunen M, Reitz C, Mateo I, Feulner T, Bullido M, Galimberti D, Concar L, Alvarez V, Sims R, Gerrish A, Chapman J, Deniz-Naranjo C, Solfrizzi V, Sorbi S, Arosio B, Spalletta G, Siciliano G, Epelbaum J, Hannequin D, Dartigues JF, Tzourio C, Berr C, Schrijvers EM, Rogers R, Tosto G, Pasquier F, Bettens K, Van Cauwenberghe C, Fratiglioni L, Graff C, Delepine M, Ferri R, Reynolds CA, Lannfelt L, Ingelsson M, Prince JA, Chillotti C, Pilotto A, Seripa D, Boland A, Mancuso M, Bossù P, Annoni G, Nacmias B, Bosco P, Panza F, Sanchez-Garcia F, Del Zompo M, Coto E, Owen M, O'Donovan M, Valdivieso F, Caffara P, Scarpini E, Combarros O, Buée L, Champion D, Soininen H, Breteler M, Riemenschneider M, Van Broeckhoven C, Alperovitch A, Lathrop M, Trégouët DA, Williams J, Amouyel P. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. **Molecular Psychiatry** 2013;18:461-70.
238. Giunta M, Rigamonti AE, Bonomo SM, Gagliano MG, Müller EE, Scarpini E, Galimberti D, Cella SG. Estrogens need IGF-1 cooperation to exert their neuroprotective effects in postmenopausal women. **Journal of Endocrinological Investigation** 2013 Feb;36(2):97-103.
239. Albani D, Boneschi FM, Biella G, Giacalone G, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Mariani S, Confaloni A, Bruno G, Mariani C, Scarpini E, Binetti G, Magnani G, Franceschi M, Forloni G. Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. **Journal of Alzheimer's Disease** 2012;30(4):745-9.
240. Galimberti D, Dell'Osso B, Fenoglio C, Villa C, Cortini F, Serpente M, Kittel-Schneider S, Weigl J, Neuner M, Volkert J, Leonhard C, Olmes DG, Kopf J, Cantoni C, Ridolfi E, Palazzo C, Ghezzi L, Bresolin N, Altamura AC, Scarpini E, Reif A. Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. **PLoS One** 2012;7(4):e32164.
241. Galimberti D, Scarpini E. Clinical phenotypes and genetic biomarkers of FTL. **Journal of Neural Transmission** 2012;119(7):851-60.
242. Galimberti D, Scarpini E. Genetics of frontotemporal lobar degeneration. **Frontiers in Neurology** 2012;3:52.
243. Cerami C, Scarpini E, Cappa SF, Galimberti D. Frontotemporal lobar degeneration: current knowledge and future challenges. **Journal of Neurology** 2012;259:2278-86.
244. Arighi A, Fumagalli GG, Jacini F, Fenoglio C, Ghezzi L, Pietroboni AM, De Riz M, Serpente M, Ridolfi E, Bonsi R, Bresolin N, Scarpini E, Galimberti D. Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations. **Journal of Alzheimer's Disease** 2012;31(2):447-52.

245. Crimella C, Baschiroto C, Arnoldi A, Tonelli A, Tenderini E, Airoidi G, Martinuzzi A, Trabacca A, Losito L, Scarlato M, Benedetti S, Scarpini E, Spinicci G, Bresolin N, Bassi MT. Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot-Marie-Tooth type 2. **Clinical Genetics** 2012;82(2):157-64.
246. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, Capello E, Currò D, Uccelli A, Bertolotto A, Gasperini C, Lugaresi A, Merelli E, Meucci G, Motti L, Tola MR, Scarpini E, Repice AM, Massacesi L, Saccardi R; Italian BMT Study Group. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. **Multiple Sclerosis** 2012;18(6):835-42.
247. Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group (including Scarpini E). Patient adherence to and tolerability of self-administered interferon β -1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. **BMC Neurology** 2012;12:7.
248. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group (including Scarpini E). Placebo-controlled trial of oral laquinimod for multiple sclerosis. **New England Journal Medicine** 2012;366(11):1000-9.
249. Boggio PS, Ferrucci R, Mameli F, Martins D, Martins O, Vergari M, Tadini L, Scarpini E, Fregni F, Priori A. Prolonged visual memory enhancement after direct current stimulation in Alzheimer's disease. **Brain Stimulation** 2012;5(3):223-30.
250. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. **Journal of Alzheimer's Disease** 2012;31(1):225-36.
251. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C; Memantine Lombardy Study Group (including Scarpini E). Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. **Neurological Sciences** 2012;33(1):23-31.
252. Villa C, Ghezzi L, Fenoglio C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Serpente M, Cantoni C, Ridolfi E, Bonsi R, Cerami C, Cappa S, Binetti G, Franceschi M, Rainero I, Mariani C, Bresolin N, Scarpini E, Galimberti D. Genetics and Expression Analysis of the Specificity Protein 4 Gene (SP4) in Patients with Alzheimer's Disease and Frontotemporal Lobar Degeneration. **Journal of Alzheimer's Disease** 2012;31(3):537-42.
253. Polito L, Kehoe PG, Davin A, Benussi L, Ghidoni R, Binetti G, Quadri P, Lucca U, Tettamanti M, Clerici F, Bagnoli S, Galimberti D, Nacmias B, Sorbi S, Guaita A, Scarpini E, Mariani C, Forloni G, Albani D. The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. **Alzheimers & Dementia** 2013;9(4):392-9.
254. D'Addario C, Di Francesco A, Arosio B, Gussago C, Dell'osso B, Bari M, Galimberti D, Scarpini E, Altamura AC, Mari D, Maccarrone M. Epigenetic regulation of Fatty Acid amide hydrolase in Alzheimer disease. **PLoS One** 2012;7(6):e39186.
255. Rubino E, Rainero I, Chiò A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G, Calvo A, Gentile S, Bruni AC, St George-Hyslop PH, Scarpini E, Gallone S, Pinessi L; For the TODem Study Group. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **Neurology** 2012;79(15):1556-62.
256. Galimberti D, Scarpini E. Progress in multiple sclerosis research in the last year. **Journal of Neurology** 2012; 259(7):1497-501.
257. D'Addario C, Dell'osso B, Galimberti D, Palazzo MC, Benatti B, Di Francesco A, Scarpini E, Altamura AC, Maccarrone M. Epigenetic Modulation of BDNF Gene in Patients with Major Depressive Disorder. **Biological Psychiatry** 2013;15;73(2):e6-7.
258. Galimberti D, D'Addario C, Dell'Osso B, Fenoglio C, Marcone A, Cerami C, Cappa SF, Palazzo MC, Arosio B, Mari D, Maccarrone M, Bresolin N, Altamura AC, Scarpini E. Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. **Neurological Sciences** 2013;34(6):899-903.
259. Comi C, Cappellano G, Chiocchetti A, Orilieri E, Buttini S, Ghezzi L, Galimberti D, Guerini F, Barizzzone N, Perla F, Leone M, D'Alfonso S, Caputo D, Scarpini E, Cantello R, Dianzani U. The impact of osteopontin gene variations on multiple sclerosis development and progression. **Clinical and Developmental Immunology** 2012;2012:212893.
260. Tiloca C, Ticozzi N, Pensato V, Corrado L, Del Bo R, Bertolin C, Fenoglio C, Gagliardi S, Calini D, Lauria G, Castellotti B, Bagarotti A, Corti S, Galimberti D, Cagnin A, Gabelli C, Ranieri M, Ceroni M, Siciliano G, Mazzini L, Cereda C, Scarpini E, Sorarù G, Comi GP, D'Alfonso S, Gellera C, Ratti A, Landers JE, Silani V; SLAGEN Consortium. Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. **Neurobiology of Aging** 34(5):1517.e9-10.

261. Ghezzi L, Scarpini E, Rango M, Arighi A, Bassi MT, Tenderini E, De Riz M, Jacini F, Fumagalli GG, Pietroboni AM, Galimberti D, Bresolin N. A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val EIF2B3 mutation. **Neurology** 2012;79(20):2077-8.
262. Clerici F, Caracciolo B, Cova I, Fusari Imperatori S, Maggiore L, Galimberti D, Scarpini E, Mariani C, Fratiglioni L. Does Vascular Burden Contribute to the Progression of Mild Cognitive Impairment to Dementia?. **Dementia and Geriatric Cognitive Disorders** 2012;34(3-4):235-243.
263. Fenoglio C, Ridolfi E, Galimberti D, Scarpini E. MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis. **International Journal of Molecular Science** 2012;13(10):13227-39.
264. Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. **Journal of the Neurological Sciences** 2013 Jan 5. doi:pii: S0022-510X(12)00637-5. 10.1016/j.jns.2012.12.013. [Epub ahead of print].
265. Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, Santangelo R, Brambilla P, Esposito F, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Confaloni A, Bruno G, Pichler S, Mayhaus M, Riemenschneider M, Mariani C, Comi G, Scarpini E, Binetti G, Forloni G, Franceschi M, Albani D. Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. **Neurobiology of Aging** 2013; 34(6):1711.e7-13.
266. Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaesi A, Rovaris M, Patti F, Capello E, Rodegher ME, Moiola L, Malucchi S, Salemi G, De Rossi N, Provinciali L, Perini P, Bergamaschi R, Scarpini E, Lus G, Gallo A, Tola MR, Amato MP, Rottoli MR, Bianchi A, Comi G; The MS Study Group-Italian Society of Neurology. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. **Neurological Sciences** 2013;34(9):1633-7.
267. Ridolfi E, Fenoglio C, Cantoni C, Calvi A, De Riz M, Pietroboni A, Villa C, Serpente M, Bonsi R, Vercellino M, Cavalla P, Galimberti D, Scarpini E. Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. **International Journal of Molecular Science** 2013;14(3):4375-84.
268. Cerami C, Marcone A, Galimberti D, Zamboni M, Fenoglio C, Serpente M, Scarpini E, Cappa SF. Novel Evidence of Phenotypical Variability in the Hexanucleotide Repeat Expansion in Chromosome 9. **Journal of Alzheimer's Disease** 2013;35(3):455-62.
269. Villa C, Ridolfi E, Fenoglio C, Ghezzi L, Vimercati R, Clerici F, Marcone A, Gallone S, Serpente M, Cantoni C, Bonsi R, Cioffi S, Cappa S, Franceschi M, Rainero I, Mariani C, Scarpini E, Galimberti D. Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease. **Journal of Alzheimer's Disease** 2013;35(3):487-94.
270. Piscopo P, Rivabene R, Galimberti D, Crestini A, Talarico G, Vanacore N, Scarpini E, Bruno G, Confaloni A. Gender Effects on Plasma PGRN Levels in Patients with Alzheimer's Disease: A Preliminary Study. **Journal of Alzheimer's Disease** 2013; 35(2): 313-8.
271. Arosio B, Abbate C, Galimberti D, Rossi PD, Inglese S, Fenoglio C, Ridolfi E, Gussago C, Casati M, Tedone E, Ferri E, Serpente M, Scarpini E, Mari D. GRN Thr272fs Clinical Heterogeneity: A Case with Atypical Late Onset Presenting with a Dementia with Lewy Bodies Phenotype. **Journal of Alzheimer's Disease** 2013;35(4):669-74.
272. Galimberti D, Fenoglio C, Serpente M, Villa C, Bonsi R, Arighi A, Fumagalli GG, Del Bo R, Bruni AC, Anfossi M, Clodimiro A, Cupidi C, Nacmias B, Sorbi S, Piaceri I, Bagnoli S, Bessi V, Marcone A, Cerami C, Cappa SF, Filippi M, Agosta F, Magnani G, Comi G, Franceschi M, Rainero I, Giordana M, Rubino E, Ferrero P, Rogaeva E, Xi Z, Confaloni A, Piscopo P, Bruno G, Talarico G, Cagnin A, Clerici F, Dell' Osso B, Comi GP, Altamura AC, Mariani C, Scarpini E. Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. **Biological Psychiatry** 2013;74:384-91.
273. Cerami C, Marcone A, Galimberti D, Villa C, Fenoglio C, Scarpini E, Cappa SF. Novel Missense Progranulin Gene Mutation Associated with the Semantic Variant of Primary Progressive Aphasia. **Journal of Alzheimer's Disease** 2013;36(3):415-20.
274. Galimberti D, Scarpini E. Progress in Alzheimer's disease research in the last year. **Journal of Neurology** 2013; 260(7):1936-41.
275. Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S. Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy. **American Journal of Epidemiology** 2013;178:1139-45.
276. Fenoglio C, Ridolfi E, Galimberti D, Scarpini E. An Emerging Role for Long Non-Coding RNA Dysregulation in Neurological Disorders. **International Journal of Molecular Science** 2013;14(10):20427-42.
277. Galimberti D, Arosio B, Fenoglio C, Serpente M, Cioffi SM, Bonsi R, Rossi P, Abbate C, Mari D, Scarpini E. Incomplete Penetrance of the C9ORF72 Hexanucleotide Repeat Expansions: Frequency in a Cohort of Geriatric Non-Demented Subjects. **Journal of Alzheimer's Disease** 2014;39(1):19-22.

278. Carecchio M, Galimberti D, Fenoglio C, Serpente M, Scarpini E, Comi C, Terazzi E, Cantello R. Evidence of Pre-Synaptic Dopaminergic Deficit in a Patient with a Novel Progranulin Mutation Presenting with Atypical Parkinsonism. **Journal of Alzheimer's Disease** 2014;38(4):747-52.
279. Galimberti D, Scarpini E. Dementia: not only Alzheimer's disease, an eye on frontotemporal dementia. **Acta Medica Portuguesa** 2013;26(4):299-300.
280. Ridolfi E, Barone C, Scarpini E, Galimberti D. The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. **Clinical and Developmental Immunology** 2013;2013:939786.
281. Grande G, Vanacore N, Maggiore L, Cucumo V, Ghiretti R, Galimberti D, Scarpini E, Mariani C, Clerici F. Physical Activity Reduces the Risk of Dementia in Mild Cognitive Impairment Subjects: A Cohort Study. **Journal of Alzheimer's Disease** 2014;39(4):833-9.
282. Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. **Multiple Sclerosis** 2013;19:1938-42.
283. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F; European Alzheimer's Disease Initiative (EADI, including Scarpini E), et al. **Nature Genetics** 2013;45(12):1452-8.
284. Pietroboni A, Arighi A, Deriz M, Scarpini E, Galimberti D, Bresolin N, Rango M. Brain temperature in multiple sclerosis. **Multiple Sclerosis** 2014;20(7):894-6.
285. Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C, Gennarelli M, Turla M, Scarpini E, Sorbi S, Padovani A. Heterozygous TREM2 mutations in frontotemporal dementia. **Neurobiology of Aging** 2014;35(4):934.e7-10.
286. Calvi A, De Riz M, Pietroboni AM, Ghezzi L, Maltese V, Arighi A, Fumagalli GG, Jacini F, Donelli C, Comi G, Galimberti D, Scarpini E. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. **Immunotherapy** 2014;6(1):23-8.
287. Galimberti D, Reif A, Dell'osso B, Palazzo C, Villa C, Fenoglio C, Kittel-Schneider S, Leonhard C, Olmes DG, Serpente M, Paoli RA, Altamura AC, Scarpini E. C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. **Bipolar Disorders** 2014;16(4):448-9.
288. Ferrucci R, Vergari M, Cogiamanian F, Bocci T, Ciocca M, Tomasini E, De Riz M, Scarpini E, Priori A. Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis. **NeuroRehabilitation** 2014;34(1):121-7.
289. Sorosina M, Brambilla P, Clarelli F, Barizzone N, Lupoli S, Guaschino C, Osiceanu AM, Moiola L, Ghezzi A, Coniglio G, Patti F, Mancardi G, Manunta P, Glorioso N, Guerini FR, Bergamaschi R, Perla F; PROGRESSO; PROGEMUS (including Scarpini E), Martinelli V, Cusi D, Leone M, Comi G, D'Alfonso S, Martinelli-Boneschi F. Genetic burden of common variants in progressive and bout-onset multiple sclerosis. **Multiple Sclerosis** 2014;20(7):802-11.
290. Angiari S, Rossi B, Piccio L, Zinselmeyer BH, Budui S, Zenaro E, Della Bianca V, Bach SD, Scarpini E, Bolomini-Vittori M, Piacentino G, Dusi S, Laudanna C, Cross AH, Miller MJ, Constantin G. Regulatory T Cells Suppress the Late Phase of the Immune Response in Lymph Nodes through P-Selectin Glycoprotein Ligand-1. **Journal of Immunology** 2013;191(11):5489-500.
291. Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group (Including Scarpini E). Subcutaneous interferon β -1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. **PLoS One** 2013;8(8):e74111.
292. Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; on behalf of the ALLEGRO Study Group (including Scarpini E). Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. **Journal of Neurology, Neurosurgery & Psychiatry** 2014 Aug;85(8):851-8.
293. Ross J, Sharma S, Winston J, Nunez M, Bottini G, Franceschi M, Scarpini E, Frigerio E, Fiorentini F, Fernandez M, Sivilia S, Giardino L, Calza L, Norris D, Cicirello H, Casula D, Imbimbo BP. CHF5074 reduces

- biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. **Current Alzheimer Research** 2013;10:742-53.
294. Scheltens P, Twisk JW, Blesa R, [Scarpini E](#), von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. **Journal of Alzheimer's Disease** 2012;31(1):225-36.
 295. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Käser SA; Alzheimer's Association QC Program Work Group (including [Scarpini E](#)). CSF biomarker variability in the Alzheimer's Association quality control program. **Alzheimer's & Dementia** 2013;9(3):251-61.
 296. Ghezzi L, [Scarpini E](#), Galimberti D. Disease-modifying drugs in Alzheimer's disease. **Drug Design Development Therapy** 2013;7:1471-9.
 297. Galimberti D, Reif A, Dell'osso B, Kittel-Schneider S, Leonhard C, Herr A, Palazzo C, Villa C, Fenoglio C, Serpente M, Cioffi SM, Prunas C, Paoli RA, Altamura AC, [Scarpini E](#). The C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. **Neurobiology of Aging** 2014; 35(5):1214.e7-1214.e10.
 298. Fenoglio C, De Riz M, Villa C, Serpente M, Ridolfi E, Bonsi R, Cioffi SM, Barone C, Pietroboni A, Calvi A, [Scarpini E](#), Galimberti D. C9ORF72 repeat expansion not detected in patients with multiple sclerosis. **Neurobiology of Aging** 2014; 35(5):1213.e1-2.
 299. Galimberti D, Prunas C, Paoli RA, Dell'osso B, Fenoglio C, Villa C, Palazzo C, Cigliobianco M, Camuri G, Serpente M, [Scarpini E](#), Altamura AC. Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. **Bipolar Disorders** 2014;16(7):769-72.
 300. Abbate C, Arosio B, Galimberti D, Nicolini P, Rossi PD, Ferri E, Gussago C, Deriz M, Fenoglio C, Serpente M, [Scarpini E](#), Mari D. Phenotypic Variability associated with the C9ORF72 Hexanucleotide Repeat Expansion: A Sporadic Case of Frontotemporal Lobar Degeneration with Prodromal Hyposmia and Predominant Semantic Deficits. **Journal of Alzheimer's Disease** 2014; 40(4):849-55.
 301. Serpente M, Bonsi R, [Scarpini E](#), Galimberti D. Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment. **Neuroimmunomodulation** 2014;21:79-87.
 302. Guerini FR, Clerici M, Cagliani R, Malhotra S, Montalban X, Forni D, Agliardi C, Riva S, Caputo D, Galimberti D, Asselta R, Fenoglio C, [Scarpini E](#), Comi GP, Bresolin N, Comabella M, Sironi M. No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. **Journal of Neuroimmunology** 2014;271(1-2):49-52.
 303. Escott-Price V, Bellenguez C, Wang LS, Choi SH, Harold D, Jones L, Holmans P, Gerrish A, Vedernikov A, Richards A, DeStefano AL, Lambert JC, Ibrahim-Verbaas CA, Naj AC, Sims R, Jun G, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Denning N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Schmidt H, Kunkle B, Dunstan ML, Vronskaya M; the United Kingdom Brain Expression Consortium, Johnson AD, Ruiz A, Bihoreau MT, Reitz C, Pasquier F, Hollingworth P, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Hernández I, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, George-Hyslop PS, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Garcia FS, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, [Scarpini E](#), et al. Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. **PLoS One** 2014;9(6):e94661.
 304. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM, Hodges JR, Piguet O, Bartley L, Thompson E, Haan E, Hernández I, Ruiz A, Boada M, Borroni B, Padovani A, Cruchaga C, Cairns NJ, Benussi L, Binetti G, Ghidoni R, Forloni G, Galimberti D, Fenoglio C, Serpente M, [Scarpini E](#), et al. Frontotemporal dementia and its subtypes: a genome-wide association study. **Lancet Neurology** 2014;13(7):686-99.
 305. Gallone S, Boschi S, Rubino E, De Martino P, [Scarpini E](#), Galimberti D, Fenoglio C, Acutis PL, Maniaci MG, Pinessi L, Rainero I. Is HCRTR2 a Genetic Risk Factor for Alzheimer's Disease? **Dementia & Geriatric Cognitive Disorders** 2014;38(3-4):245-53.
 306. Dell'Osso B, D'Addario C, Carlotta Palazzo M, Benatti B, Camuri G, Galimberti D, Fenoglio C, [Scarpini E](#), Di Francesco A, Maccarrone M, Carlo Altamura A. Epigenetic modulation of BDNF gene: Differences in DNA methylation between unipolar and bipolar patients. **Journal of Affective Disorders** 2014;166:330-3.
 307. Guerini FR, Agliardi C, Sironi M, Arosio B, Calabrese E, Zanzottera M, Bolognesi E, Ricci C, Costa AS, Galimberti D, Griffanti L, Bianchi A, Savazzi F, Mari D, [Scarpini E](#), Baglio F, Nemni R, Clerici M. Possible

- Association between SNAP-25 Single Nucleotide Polymorphisms and Alterations of Categorical Fluency and Functional MRI Parameters in Alzheimer's Disease. **Journal of Alzheimer's Disease** 2014;42(3):1015-28.
308. Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SM, Arighi A, Fumagalli G, Scarpini E. Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease. **Journal of Alzheimer's Disease** 2014;42(4):1261-7.
 309. Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-Péchoux S, Camuzat A, Clot F, Fenoglio C; The French research network on FTD and FTD-ALS, Scarpini E, Brice A, Kabashi E. Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. **Neurobiology of Aging** 2014;35:2658.e1-5.
 310. Serpente M, Fenoglio C, Clerici F, Bonsi R, Arosio B, Cioffi SM, Rotondo E, Franceschi M, Boneschi FM, Mari D, Mariani C, Scarpini E, Galimberti D. Transmembrane Protein 106B Gene (TMEM106B) Variability and Influence on Progranulin Plasma Levels in Patients with Alzheimer's Disease. **Journal of Alzheimer's Disease** 2015; 43(3):757-61.
 311. Talarico G, Canevelli M, Tosto G, Piscopo P, Confaloni A, Galimberti D, Fenoglio C, Scarpini E, Gasparini M, Bruno G. Binge eating and fast cognitive worsening in an early-onset bvFTD patient carrying C9ORF72 expansion. **Neurocase** 2014;26:1-5.
 - 312.27. Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C. Detection of misfolded A β oligomers for sensitive biochemical diagnosis of Alzheimer's disease. **Cell Reports** 2014; 7(1):261-8.
 313. Ferrucci R, Vergari M, Cogiamanian F, Bocci T, Ciocca M, Tomasini E, De Riz M, Scarpini E, Priori A. Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis. **Neurorehabilitation** 2014;34(1):121-7.
 314. Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; ALLEGRO Study Group (including Scarpini E). Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. **J Neurol Neurosurg Psychiatry**. 2014;85:851-8.
 315. Calvi A, Cioffi SM, Caffarra P, Fenoglio C, Serpente M, Pietroboni AM, Arighi A, Ghezzi L, Gardini S, Scarpini E, Galimberti D. The Novel GRN g.1159_1160delTG Mutation is Associated with Behavioral Variant Frontotemporal Dementia. **Journal of Alzheimer's Disease** 2015;44(1):277-82.
 316. Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, Sorbi S, Scarpini E, Padovani A. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. **Amyotroph Lateral Scler Frontotemporal Degener** 2015;16(1-2):86-91.
 317. Borroni B, Turrone R, Galimberti D, Nacmias B, Alberici A, Benussi A, Caffarra P, Caltagirone C, Cappa SF, Frisoni GB, Ghidoni R, Marra C, Padovani A, Rainero I, Scarpini E, Silani V, Sorbi S, Tagliavini F, Tremolizzo L, Bruni AC; The FTD Group-SINDEM. Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. **Neurological Sciences** 2015;36(5):751-7.
 318. Serpente M, Fenoglio C, Cioffi SM, Bonsi R, Arighi A, Fumagalli GG, Ghezzi L, Scarpini E, Galimberti D. Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations. **International Journal of Molecular Science** 2015;16(1):1385-1394.
 319. Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, van Minkelen R, Rombouts SA, Cardoso MJ, Clegg S, Espak M, Mead S, Thomas DL, De Vita E, Masellis M, Black SE, Freedman M, Keren R, MacIntosh BJ, Rogaeva E, Tang-Wai D, Tartaglia MC, Laforce R Jr, Tagliavini F, Tiraboschi P, Redaelli V, Prioni S, Grisoli M, Borroni B, Padovani A, Galimberti D, Scarpini E, Arighi A, Fumagalli G, Rowe JB, Coyle-Gilchrist I, Graff C, Fallström M, Jelic V, Ståhlbom AK, Andersson C, Thonberg H, Lilius L, Frisoni GB, Pievani M, Bocchetta M, Benussi L, Ghidoni R, Finger E, Sorbi S, Nacmias B, Lombardi G, Polito C, Warren JD, Ourselin S, Fox NC, Rossor MN. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. **Lancet Neurology** 2015;14(3):253-62.
 320. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick J, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Drenzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño J, Kleinová P, Horáková D, Roesler R, Lauda F, Llufríu S, Avsar T, Uygungölu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. **Multiple Sclerosis** 2015;21(8):1013-24.
 321. Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, Piehl F, Bartos A, Zimova D, Kotoucová J, Kuhle J, Kappos L, García-Merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. **Brain** 2015;138(Pt 4):918-31.

322. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, Kunkle BW, Wang LS, Bis JC, Bellenguez C, Harold D, Lunetta KL, Destefano AL, Grenier-Boley B, Sims R, Beecham GW, Smith AV, Chouraki V, Hamilton-Nelson KL, Ikram MA, Fievet N, Denning N, Martin ER, Schmidt H, Kamatani Y, Dunstan ML, Valladares O, Laza AR, Zelenika D, Ramirez A, Foroud TM, Choi SH, Boland A, Becker T, Kukull WA, van der Lee SJ, Pasquier F, Cruchaga C, Beekly D, Fitzpatrick AL, Hanon O, Gill M, Barber R, Gudnason V, Campion D, Love S, Bennett DA, Amin N, Berr C, Tsolaki M, Buxbaum JD, Lopez OL, Deramecourt V, Fox NC, Cantwell LB, Tarraga L, Dufouil C, Hardy J, Crane PK, Eiriksdottir G, Hannequin D, Clarke R, Evans D, Mosley TH Jr, Letenneur L, Brayne C, Maier W, De Jager P, Emilsson V, Dartigues JF, Hampel H, Kamboh MI, de Bruijn RF, Tzourio C, Pastor P, Larson EB, Rotter JI, O'Donovan MC, Montine TJ, Nalls MA, Mead S, Reiman EM, Jonsson PV, Holmes C, St George-Hyslop PH, Boada M, Passmore P, Wendland JR, Schmidt R, Morgan K, Winslow AR, Powell JF, Carasquillo M, Younkin SG, Jakobsdóttir J, Kauwe JS, Wilhelmsen KC, Rujescu D, Nöthen MM, Hofman A, Jones L; IGAP Consortium (including [Scarpini E](#)), Haines JL, Psaty BM, Van Broeckhoven C, Holmans P, Launer LJ, Mayeux R, Lathrop M, Goate AM, Escott-Price V, Seshadri S, Pericak-Vance MA, Amouyel P, Williams J, van Duijn CM, Schellenberg GD, Farrer LA. A novel Alzheimer disease locus located near the gene encoding tau protein. **Molecular Psychiatry** 2016;21(1):108-17.
323. Piscopo P, Tosto G, Belli C, Talarico G, Galimberti D, Gasparini M, Canevelli M, Poleggi A, Crestini A, Albani D, Forloni G, Lucca U, Quadri P, Tettamanti M, Fenoglio C, [Scarpini E](#), Bruno G, Vanacore N, Confaloni A. SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease **Journal of Alzheimer's Disease** 2015 46(3):771-6.
324. Galimberti D, Dell'Osso B, Altamura AC, [Scarpini E](#). Psychiatric Symptoms in Frontotemporal Dementia: Epidemiology, Phenotypes, and Differential Diagnosis. **Biological Psychiatry** 2015;78(10):684-92.
325. Galimberti D, [Scarpini E](#). Idalopirdine as a treatment for Alzheimer's disease. **Expert Opinion on Investigation Drugs** 2015;24(7):981-7.
326. Galimberti D, Bonsi R, Fenoglio C, Serpente M, Cioffi SM, Fumagalli G, Arighi A, Ghezzi L, Arcaro M, Mercurio M, Rotondo E, [Scarpini E](#). Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. **Brain Behaviour & Immunity** 2015;49:182-7.
327. Pietroboni AM, Arighi A, De Riz MA, Ghezzi L, Calvi A, Avignone S, Scola E, Galimberti D, Triulzi F, [Scarpini E](#). Baló's concentric sclerosis: still to be considered as a variant of multiple sclerosis? **Neurological Sciences** 2015;36(12):2277-80.
328. Ferrari R, Grassi M, Salvi E, Borroni B, Palluzzi F, Pepe D, D'Avila F, Padovani A, Archetti S, Rainero I, Rubino E, Pinessi L, Benussi L, Binetti G, Ghidoni R, Galimberti D, [Scarpini E](#), Serpente M, Rossi G, Giaccone G, Tagliavini F, Nacmias B, Piaceri I, Bagnoli S, Bruni AC, Maletta RG, Bernardi L, Postiglione A, Milan G, Franceschi M, Puca AA, Novelli V, Barlassina C, Glorioso N, Manunta P, Singleton A, Cusi D, Hardy J, Momeni P. A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. **Neurobiology of Aging** 2015;36(10):2904.e13-26.
329. Vercellino M, Fenoglio C, Galimberti D, Mattioda A, Chiavazza C, Binello E, Pinessi L, Giobbe D, [Scarpini E](#), Cavalla P. Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. **Multiple Sclerosis** 2016;22(8):1007-12.
330. Arighi A, Rango M, Bozzali M, Pietroboni AM, Fumagalli G, Ghezzi L, Fenoglio C, Biondetti PR, Bresolin N, Galimberti D, [Scarpini E](#). Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. **PLoS One** 2015;10(10):e0140639.
331. Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinos NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, [Scarpini E](#), Schott JM, Fox NC, Hardy J, Bahtia K, Heales S, Sebire NJ, Zetterburg H, Mills K. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. **Molecular Neurodegeneration** 2015;10(1):64.
332. Olde Rikkert MG, Verhey FR, Blesa R, von Arnim CA, Bongers A, Harrison J, Sijben J, [Scarpini E](#), Vandewoude MF, Vellas B, Witkamp R, Kamphuis PJ, Scheltens P. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. **Journal of Alzheimer's Disease** 2015;44(2):471-80.
333. Bellelli G, Morandi A, Di Santo SG, Mazzone A, Cherubini A, Mossello E, Bo M, Bianchetti A, Rozzini R, Zanetti E, Musicco M, Ferrari A, Ferrara N, Trabucchi M; Italian Study Group on Delirium (ISGoD, including [Scarpini E](#)). "Delirium Day": a nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool. **BMC Medicine** 2016;14:106.
334. Montanari E, Rottoli M, Maimone D, Confalonieri P, Plewnia K, Frigo M, Francia A, Pala A, Losignore NA, Ragonese P, Veneziano A; POSIDONIA study group (including [Scarpini E](#)). A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study. **Journal of the Neurological Sciences** 2016;364:105-9.

335. Gazzina S, Premi E, Zanella I, Biasiotto G, Archetti S, Cosseddu M, [Scarpini E](#), Galimberti D, Serpente M, Gasparotti R, Padovani A, Borroni B. Iron in Frontotemporal Lobar Degeneration: A New Subcortical Pathological Pathway? **Neurodegenerative Diseases** 2016;16(3-4):172-8.
336. Grande G, Cucumo V, Cova I, Ghiretti R, Maggiore L, Lacorte E, Galimberti D, [Scarpini E](#), Clerici F, Pomati S, Vanacore N, Mariani C. Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation. **Journal of Alzheimer's Disease** 2016;51(1):57-67.
337. Galimberti D, [Scarpini E](#). Emerging amyloid disease-modifying drugs for Alzheimer's disease. **Expert Opinion on Emerging Drugs** 2016;21(1):5-7
338. Oldoni E, Fumagalli GG, Serpente M, Fenoglio C, Scarioni M, Arighi A, Bruno G, Talarico G, Confaloni A, Piscopo P, Nacmias B, Sorbi S, Rainero I, Rubino E, Pinessi L, Binetti G, Ghidoni R, Benussi L, Grande G, Arosio B, Bursey D, Kauwe JS, Cioffi SM, Arcaro M, Mari D, Mariani C, [Scarpini E](#), Galimberti D. PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. **Journal of Alzheimer's Disease** 2016;50(2):353-7.
339. Bocchetta M, Mega A, Bernardi L, Di Maria E, Benussi L, Binetti G, Borroni B, Colao R, Di Fede G, Fostinelli S, Galimberti D, Gennarelli M, Ghidoni R, Piaceri I, Pievani M, Porteri C, Redaelli V, Rossi G, Suardi S, Babiloni C, [Scarpini E](#), Tagliavini F, Padovani A, Nacmias B, Sorbi S, Frisoni GB, Bruni AC; SINDem. Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. **Journal of Alzheimer's Disease** 2016;51(1):277-91.
340. Cova I, Clerici F, Maggiore L, Pomati S, Cucumo V, Ghiretti R, Galimberti D, [Scarpini E](#), Mariani C, Caracciolo B. Body Mass Index Predicts Progression of Mild Cognitive Impairment to Dementia. **Dementia and Geriatric Cognitive Disorders** 2016;41(3-4):172-80.
341. Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, Yong KX, Lehmann M, Ertekin-Taner N, Graff-Radford NR, Boeve BF, Murray ME, Khan QU, Petersen RC, Dickson DW, Knopman DS, Rabinovici GD, Miller BL, Gonzalez AS, Gil-Neciga E, Snowden JS, Harris J, Pickering-Brown SM, Louwersheimer E, van der Flier WM, Scheltens P, Pijnenburg YA, Galasko D, Sarazin M, Dubois B, Magnin E, Galimberti D, [Scarpini E](#), Cappa SF, Hodges JR, Halliday GM, Bartley L, Carrillo MC, Bras JT, Hardy J, Rossor MN, Collinge J, Fox NC, Mead S. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. **Alzheimers & Dementia** 2016;12(8):862-71.
342. Cova I, Clerici F, Rossi A, Cucumo V, Ghiretti R, Maggiore L, Pomati S, Galimberti D, [Scarpini E](#), Mariani C, Caracciolo B. Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer's Disease. **PLoS One** 2016;11(3):e0151710.
343. Ferri E, Arosio B, D'Addario C, Galimberti D, Gussago C, Pucci M, Casati M, Fenoglio C, Abbate C, Rossi PD, [Scarpini E](#), Maccarrone M, Mari D. Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease. **Journal of the Neurological Sciences** 2016;362:283-6.
344. Clarelli F, Mascia E, Santangelo R, Mazzeo S, Giacalone G, Galimberti D, Fusco F, Zuffi M, Fenoglio C, Franceschi M, [Scarpini E](#), Forloni G, Magnani G, Comi G, Albani D, Martinelli Boneschi F. CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. **Journal of Alzheimer's Disease** 2016;52(4):1203-8.
345. Marceglia S, Mrakic-Sposta S, Rosa M, Ferrucci R, Mameli F, Vergari M, Arlotti M, Ruggiero F, [Scarpini E](#), Galimberti D, Barbieri S, Priori A. Transcranial Direct Current Stimulation Modulates Cortical Neuronal Activity in Alzheimer's Disease. **Frontiers in Neuroscience** 2016 Mar 31;10:134.
346. Galimberti D, Bertram K, Formica A, Fenoglio C, Cioffi SM, Arighi A, [Scarpini E](#), Colosimo C. Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes. **Journal of Alzheimer's Disease** 2016;53(2):445-9.
347. Neven KY, Piola M, Angelici L, Cortini F, Fenoglio C, Galimberti D, Pesatori AC, [Scarpini E](#), Bollati V. Repetitive element hypermethylation in multiple sclerosis patients. **BMC Genetics** 2016;17(1):84.
348. Galimberti D, [Scarpini E](#). Old and new acetylcholinesterase inhibitors for Alzheimer's disease. **Expert Opinion on Investigational Drugs** 2016;25(10):1181-7.
349. Cioffi SM, Galimberti D, Barocco F, Spallazzi M, Fenoglio C, Serpente M, Arcaro M, Gardini S, [Scarpini E](#), Caffarra P. Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation. **Journal of Alzheimer's Disease** 2016;54(2):717-21.
350. Meeter LH, Dopfer EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D, Laforce RJ, Masellis M, Vandenberghe R, Ber IL, Otto M, van Minkelen R, Papma JM, Rombouts SA, Balasa M, Öijerstedt L, Jelic V, Dick KM, Cash DM, Harding SR, Jorge Cardoso M, Ourselin S, Rossor MN, Padovani A, [Scarpini E](#), Fenoglio C, Tartaglia MC, Lamari F, Barro C, Kuhle J, Rohrer JD, Teunissen CE, van Swieten JC. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. **Annals of Clinical Translational Neurology** 2016;3(8):623-36.
351. Bonanni L, Cagnin A, Agosta F, Babiloni C, Borroni B, Bozzali M, Bruni AC, Filippi M, Galimberti D, Monastero R, Muscio C, Parnetti L, Perani D, Serra L, Silani V, Tiraboschi P, Padovani A; DLB-SINdem

- study group (including [Scarpini E](#)). The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. **Neurological Sciences** 2017;38(1):83-91.
352. Sainaghi PP, Bellan M, Lombino F, Alciato F, Carecchio M, Galimberti D, Fenoglio C, [Scarpini E](#), Cantello R, Pirisi M, Comi C. Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. **Journal of Alzheimer's Disease** 2016;55(1):59-65.
 353. Fenoglio C, De Riz M, Pietroboni AM, Calvi A, Serpente M, Cioffi SM, Arcaro M, Oldoni E, [Scarpini E](#), Galimberti D. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. **Journal of Neuroimmunology** 2016;299:81-3.
 354. Pietroboni AM, Schiano di Cola F, Scarioni M, Fenoglio C, Spanò B, Arighi A, Cioffi SM, Oldoni E, De Riz MA, Basilico P, Calvi A, Fumagalli GG, Triulzi F, Galimberti D, Bozzali M, [Scarpini E](#). CSF β -amyloid as a putative biomarker of disease progression in multiple sclerosis. **Multiple Sclerosis** 2017;23(8):1085-91.
 355. Galimberti D, Scarpini E. Pioglitazone for the treatment of Alzheimer's disease. **Expert Opinion on Investigational Drugs** 2017;26(1):97-101.
 356. Galimberti D, Cioffi SM, Fenoglio C, Serpente M, Oblak AL, Rodriguez-Porcel F, Oldoni E, Hagen MC, Arcaro M, [Scarpini E](#), Ghetti B, Espay AJ. Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. **Movement Disorders** 2017;32(3):476-8.
 357. Ferrari R, Wang Y, Vandrovicova J, Guelfi S, Witeolar A, Karch CM, Schork AJ, Fan CC, Brewer JB; International FTD-Genomics Consortium (IFGC); International Parkinson's Disease Genomics Consortium (IPDGC); International Genomics of Alzheimer's Project (IGAP, including [Scarpini E](#)), Momeni P, Schellenberg GD, Dillon WP, Sugrue LP, Hess CP, Yokoyama JS, Bonham LW, Rabinovici GD, Miller BL, Andreassen OA, Dale AM, Hardy J, Desikan RS. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. **Journal of Neurology, Neurosurgery and Psychiatry** 2017;88(2):152-164.
 358. Ferrari R, Grassi M, Graziano F, Palluzzi F, Archetti S, Bonomi E, Bruni AC, Maletta RG, Bernardi L, Cupidi C, Colao R, Rainero I, Rubino E, Pinessi L, Galimberti D, [Scarpini E](#), Serpente M, Nacmias B, Piaceri I, Bagnoli S, Rossi G, Giaccone G, Tagliavini F, Benussi L, Binetti G, Ghidoni R, Singleton A, Hardy J, Momeni P, Padovani A, Borroni B. Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia. **Journal of Alzheimer's Disease** 2017;56(4):1271-8.
 359. van Waalwijk van Doorn LJ, Gisbert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, [Scarpini E](#), Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. **Journal of Alzheimer's Disease** 2017;56(2):543-55.
 360. Paroni M, Maltese V, De Simone M, Ranzani V, Larghi P, Fenoglio C, Pietroboni AM, De Riz MA, Crosti MC, Maglie S, Moro M, Caprioli F, Rossi R, Rossetti G, Galimberti D, Pagani M, [Scarpini E](#), Abrignani S, Geginat J. Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. **Journal of Allergy and Clinical Immunology** 2017;140(3):797-808.
 361. Buoli M, Serati M, Caldiroli A, Galimberti D, [Scarpini E](#), Altamura AC. Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review. **Journal of Geriatric Psychiatry and Neurology** 2017;30(3):162-9.
 362. Geginat J, Paroni M, Pagani M, Galimberti D, De Francesco R, [Scarpini E](#), Abrignani S. The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance? **Trends in Immunology** 2017;38(7):498-512.
 363. Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann P, Grove ML, Vardarajan BN, Hiltunen M, Nöthen MM, White CC, Hamilton-Nelson KL, Epelbaum J, Maier W, Choi SH, Beecham GW, Dulary C, Herms S, Smith AV, Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H, Bacq D, Harold D, Satizabal CL, Valladares O, Squassina A, Thomas R, Brody JA, Qu L, Sánchez-Juan P, Morgan T, Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage M, Malamon J, Naranjo MCD, Majounie E, Mosley TH, Dombroski B, Wallon D, Lupton MK, Dupuis J, Whitehead P, Fratiglioni L, Medway C, Jian X, Mukherjee S, Keller L, Brown K, Lin H, Cantwell LB, Panza F, McGuinness B, Moreno-Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams HH, Allen M, Seripa D, Pastor P, Cupples LA, Price ND, Hannequin D, Frank-García A, Levy D, Chakrabarty P, Caffarra P, Giegling I, Beiser AS, Giedraitis V, Hampel H, Garcia ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir G, Crane PK, Pasquier F, Boccardi V, Henández I, Barber RC, Scherer M, Tarraga L, Adams PM,

- Leber M, Chen Y, Albert MS, Riedel-Heller S, Emilsson V, Beekly D, Braae A, Schmidt R, Blacker D, Masullo C, Schmidt H, Doody RS, Spalletta G, Jr WTL, Fairchild TJ, Bossù P, Lopez OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau O, Katz MJ, Corcoran C, Dunstan M, Braddel A, Thomas C, Meggy A, Marshall R, Gerrish A, Chapman J, Aguilar M, Taylor S, Hill M, Fairén MD, Hodges A, Vellas B, Soininen H, Kloszewska I, Daniilidou M, Uphill J, Patel Y, Hughes JT, Lord J, Turton J, Hartmann AM, Cecchetti R, Fenoglio C, Serpente M, Arcaro M, Caltagirone C, Orfei MD, Ciaramella A, Pichler S, Mayhaus M, Gu W, Lleó A, Fortea J, Blesa R, Barber IS, Brookes K, Cupidi C, Maletta RG, Carrell D, Sorbi S, Moebus S, Urbano M, Pilotto A, Kornhuber J, Bosco P, Todd S, Craig D, Johnston J, Gill M, Lawlor B, Lynch A, Fox NC, Hardy J; ARUK Consortium, Albin RL, Apostolova LG, Arnold SE, Athana S, Atwood CS, Baldwin CT, Barnes LL, Barral S, Beach TG, Becker JT, Bigio EH, Bird TD, Boeve BF, Bowen JD, Boxer A, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carlsson CM, Carney RM, Carrasquillo MM, Carroll SL, Diaz CC, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, Dick M, Duara R, Evans DA, Faber KM, Fallon KB, Fardo DW, Farlow MR, Ferris S, Foroud TM, Galasko DR, Gearing M, Geschwind DH, Gilbert JR, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL, Harrell LE, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik GP, Abner E, Jin LW, Jun G, Karydas A, Kaye JA, Kim R, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lunetta KL, Lyketsos CG, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Morris JC, Murrell JR, Myers AJ, O'Bryant S, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Perry W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeve E, Rosen HJ, Rosenberg RN, Sager MA, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE, Yu L, Garzia F, Golamaully F, Septier G, Engelborghs S, Vandenberghe R, De Deyn PP, Fernandez CM, Benito YA, Thonberg H, Forsell C, Lilius L, Kihl-Ståhlbom A, Kilander L, Brundin R, Concar L, Helisalmi S, Koivisto AM, Haapasalo A, Dermecourt V, Fievet N, Hanon O, Dufouil C, Brice A, Ritchie K, Dubois B, Himali JJ, Keene CD, Tschanz J, Fitzpatrick AL, Kukull WA, Norton M, Aspelund T, Larson EB, Munger R, Rotter JJ, Lipton RB, Bullido MJ, Hofman A, Montine TJ, Coto E, Boerwinkle E, Petersen RC, Alvarez V, Rivadeneira F, Reiman EM, Gallo M, O'Donnell CJ, Reisch JS, Bruni AC, Royall DR, Dichgans M, Sano M, Galimberti D, St George-Hyslop P, Scarpini E, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. **Nature Genetics** 2017;49(9):1373-84.
364. Cova I, Grande G, Cucumo V, Ghirelli R, Maggiore L, Galimberti D, Scarpini E, Mariani C, Pomati S. Self-Awareness for Memory Impairment in Amnesic Mild Cognitive Impairment: A Longitudinal Study. **American Journal of Alzheimer's Disease and Other Dementias** 2017;32(7):401-7.
365. Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group (including Scarpini E). Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). **Journal of Neurology** 2017;264(12):2436-49.
366. Carandini T, Bozzano V, Scarpini E, Montano N, Solbiati M. Intensive versus standard lowering of blood pressure in the acute phase of intracranial haemorrhage: a systematic review and meta-analysis. **International Emergency Medicine** 2017 Aug 3. doi: 10.1007/s11739-017-1716-7. [Epub ahead of print]
367. Morandi A, Di Santo SG, Cherubini A, Mossello E, Meagher D, Mazzone A, Bianchetti A, Ferrara N, Ferrari A, Musicco M, Trabucchi M, Bellelli G; ISGoD Group (including Scarpini E). Clinical Features Associated with Delirium Motor Subtypes in Older Inpatients: Results of a Multicenter Study. **American Journal of Geriatric Psychiatry** 2017;25(10):1064-71.
368. Mutsaerts HJMM, Petr J, Thomas DL, De Vita E, Cash DM, van Osch MJP, Golay X, Groot PFC, Ourselin S, van Swieten J, Laforce R Jr, Tagliavini F, Borroni B, Galimberti D, Rowe JB, Graff C, Pizzini FB, Finger E, Sorbi S, Castelo Branco M, Rohrer JD, Masellis M, MacIntosh BJ; GENFI investigators (including Scarpini E). Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). **Journal of Magnetic Resonance Imaging**. 2017 May 8. doi: 10.1002/jmri.25751. [Epub ahead of print]
369. Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaesi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry (including Scarpini E). Prognostic indicators in pediatric clinically isolated syndrome. **Annals of Neurology** 2017 May;81(5):729-39.

370. Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group (including Scarpini E). No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. **Neurology** 2017;88(12):1144-52.
371. D'Addario C, Palazzo MC, Benatti B, Grancini B, Pucci M, Di Francesco A, Camuri G, Galimberti D, Fenoglio C, Scarpini E, Altamura AC, Maccarrone M, Dell'Osso B. Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. **Prog Neuropsychopharmacol Biol Psychiatry** 2017 Aug 19. pii: S0278-5846(17)30480-3. doi: 10.1016/j.pnpbp.2017.08.011. [Epub ahead of print]
372. Calvi A, De Riz M, Lecchi E, Pietroboni A, Ghezzi L, Scarioni M, Carandini T, Pellegrinelli A, Maurichi A, Galimberti D, Scarpini E. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod. **Journal of the Neurological Sciences** 2017;381:296-7.
373. Pietroboni AM, Scarioni M, Carandini T, Basilico P, Cadioli M, Giulietti G, Arighi A, Caprioli M, Serra L, Sina C, Fenoglio C, Ghezzi L, Fumagalli GG, De Riz MA, Calvi A, Triulzi F, Bozzali M, Scarpini E, Galimberti D. CSF β -amyloid and white matter damage: a new perspective on Alzheimer's disease. **Journal of Neurology, Neurosurgery and Psychiatry** 2017 Oct 20. pii: jnnp-2017-316603. doi: 10.1136/jnnp-2017-316603. [Epub ahead of print]
374. Galimberti D, Fumagalli GG, Fenoglio C, Cioffi SMG, Arighi A, Serpente M, Borroni B, Padovani A, Tagliavini F, Masellis M, Tartaglia MC, van Swieten J, Meeter L, Graff C, de Mendonça A, Bocchetta M, Rohrer JD, Scarpini E; Genetic FTD Initiative (GENFI). Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. **Neurobiology of Aging** 2017 Nov 13. pii: S0197-4580(17)30355-X. doi: 10.1016/j.neurobiolaging.2017.10.016. [Epub ahead of print]
375. Ghezzi L, Carandini T, Arighi A, Fenoglio C, Arcaro M, De Riz M, Pietroboni AM, Fumagalli GG, Basilico P, Calvi A, Scarioni M, Colombi A, Serpente M, Marotta G, Benti R, Scarpini E, Galimberti D. Evidence of CNS β -amyloid deposition in Nasu-Hakola disease due to the TREM2 Q33X mutation. **Neurology** 2017 Nov 15. pii: 10.1212/WNL.0000000000004747. doi: 10.1212/WNL.0000000000004747. [Epub ahead of print]

Capitoli in volume internazionali

1. Scarpini E, Galimberti D. Chemokines and their receptors in multiple sclerosis: from the role in the pathogenesis to the targeting for future treatments. In: "Treatment and Management of Multiple Sclerosis research" 2005: 89-105. Novapublishers, New York, USA (Editor: Frank Columbus).
2. Galimberti D, Fenoglio C, Scarpini E. Immunological Aspects in Neurodegenerative Disorders. In: "Neuroimmunology Research Focus" 2007: 5-42. Novapublishers, New York, USA (Editor: Paulo V. Broglio).
3. Galimberti D, Scarpini E. Role of chemokines in neurodegeneration. In: "Progress in chemokine research" 2007: 141-147. Novapublishers, New York, USA (Editor: WP Linkes).
4. Galimberti D, Fenoglio C, Scarpini E. Early onset dementia: role of genetics in the pathogenesis of Alzheimer's disease and Frontotemporal Lobar Degeneration. In: "Alzheimer Disease in the Middle-Aged", 2008: 329-245. Novapublishers, New York, USA (Editor: Hyun Sil Jeong)
5. Galimberti D, Fenoglio C, Scarpini E. Alzheimer's disease: from pathogenesis to new perspectives for treatment. In: "A Multidisciplinary Approach to Dissect the Alzheimer's Pathology" 2008: 111-129. Transworld Research Network, 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India (Editors: Roberto Dominici and Ida Biunno)
6. Galimberti D, Fenoglio C, Scarpini E. Novel Therapies for Alzheimer's Disease: Potentially Disease Modifying Drugs. In: "Cognitive Impairment: causes, diagnosis and treatments", 2009: 73-96, Novapublishers, New York, USA (Editor: Melanie L. Landow).
7. Fenoglio C, Scarpini E, Galimberti D. Gender-related genetic and biochemical differences: influence on susceptibility and course of multiple sclerosis. In: "Women and Multiple Sclerosis" 2009: 95-109, Novapublishers, New York, USA (Editor: Duane O'Mahoni and Anrai de Burca).
8. Galimberti D, Fenoglio C, Scarpini E. Genetics and Molecular Biology of Alzheimer's disease and Frontotemporal Lobar Degeneration: analogies and differences. In: "Neurodegeneration: theory, disorders and treatment" 2011: 173-88. Novapublisher, New York, USA (Editor: Alexander S. McNeill).
9. Galimberti D, Scarpini E. Behavioural genetics of neurodegenerative disorders. In: "Behavioural Neurogenetics" 2012: 615-631. Springer-Verlag, Berlin Heidelberg (Editors: John F. Cryan and Andreas Reif).
10. Galimberti D, Fenoglio C, Scarpini E. Novel therapies for Alzheimer's disease: potentially disease modifying drugs. In: "Alzheimer's disease research compendium" 2013: 73-96. Novapublishers, New York, USA (Editor: Miao-Kun Sun).

Editor volumi internazionali

1. BioMarkers for Early Diagnosis of Alzheimer's Disease 2008, Novapublishers, New York, USA
2. Neurodegenerative Diseases Clinical Aspects, Molecular Genetics and Biomarkers” 2014, Springer-Verlag, London

H-Index (Scopus): 49 (7005128369)

n. citazioni (Scopus): 9684

ORCID: 0000-0002-6395-2119

Research ID: K-6547-2016

Attività di Ricerca

1) *Coordinatore o Partecipante di unità di progetto europeo*

- The GENetic Frontotemporal Dementia Initiative (GENFI): a new multi-centre platform for the study of frontotemporal lobar degeneration – COEN 2011 – collaboratore – E 40.000,00
- Biomarkers For Alzheimer's Disease And Parkinson's Disease (Biomarkapd) – JPND 2012 – collaboratore – E 40.600
- Searching for therapeutic interventions in frontotemporal dementia with *C9ORF72* repeat expansions in the presymptomatic stage – JPND 2015 – collaboratore – E 40.000,00
- Synapse-to-nucleus communication in Alzheimer's disease (STAD) – JPND 2016 – collaboratore – E 70.000,00

2) *Coordinatore o Partecipante di unità di progetto nazionale*

- Ricerca Finalizzata RF 2010 n.2319722 - Italian Network for autosomal dominant Alzheimers disease and frontotemporal lobar degeneration – collaborator – Ministero della Salute - E 40.980,00
- Progetto di Rete NET-2011-02346784 -Development of operational research diagnostic criteria for diagnosis of Alzheimer's disease in the preclinical/predementia phase and implementation of SOPs for imaging and CSF biomarkers in Memory Clinics. An integrated care pathway for early diagnosis and best management in the National Health Service of five Italian regions – collaboratore – Ministero della Salute – E 70.000,00
- 2009 - Implementazione della diagnostica differenziale fra le diverse forme di demenze degenerative e demenze miste, e valutazione e verifica dei risultati terapeutici – collaboratore - Centro Nazionale per la Prevenzione ed il Controllo delle Malattie del Ministero della Salute E 30.000
- 2009: “Introducing new bio-markers in clinical practice for the early diagnosis of Alzheimer disease: methodological, clinical and organisational aspects for the National Health System” Progetto parte di Programma Strategico – coordinatore scientifico di unità partecipante – Ministero della Salute – E 68.000

3) *Finanziamenti competitivi*

- Fondazione Monzino: progetto collaborativo con l'Istituto Mario Negri dal titolo: “Ricerca di marcatori da associare alla patologia mediante studi genetici, proteomici e di espressione per migliorare la diagnosi e l'efficacia terapeutica” dal 2004: 2.100.000 E

4) *Ricerche cliniche: Coordinatore Nazionale*

- Continued Efficacy and Safety monitoring of solanezumab, an anti-amyloid beta antibody in patients with Alzheimer's disease, H8A-MC-LZAO
- Effect of passive Immunization on the progression of mild Alzheimer's disease: Solanezumab (LY2062430) versus Placebo, H8A-MC-LZAX
- A 6-months randomized, active comparator open label, multicenter study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5 mg day in patients with relapsing remitting multiple sclerosis who are candidates for MS therapy change from previous disease modifying therapy, CFTY720DIT02
- A Placebo-controlled, double-blind, parallel-group, Bayesian Adaptive randomization design and dose Regimen-finding Study to evaluate safety, tolerability and efficacy of BAN2401 in subjects with Early Alzheimer's Disease, EISAI, prot. BAN2401
- A randomized, double-blind, Placebo-controlled, Parallel-group, 26-week, phase 3 study of two doses of EVP-6124 or placebo in subjects with mild to moderate AD currently or previously receiving an Acetylcholinesterase Inhibitor Medication EVP-6124-025
- A randomized, Placebo Controlled, Parallel-group, Double Blind efficacy and safety Trial of MK-8931

in Subjects with mild to moderate Alzheimer's Disease, Merck Serono, MK-8931-017

- A phase III, Randomized, placebo-controlled, parallel-group, double-blind clinical trial to study the efficacy and safety of MK-8931 in subject with Amnesic Mild Cognitive Impairment due to Alzheimer's Disease (Prodromal AD), MK-8931-019
- A fase 2 multiple dose, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer Disease, ABBVIE-8612
- An observational, real life study to describe the effect of LEMTRADA on fatigue, quality of life and other patient and caregiver reported outcomes in patient with relapsing-remitting multiple sclerosis, REALITY
- A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in partecipans at risk for the onset of clinical symptoms of Alzheimer's disease (AD), CCNP520A2202J

5) *Ricerche cliniche: partecipante*

- Long term, prospective, non-interventional, multinational, parallel-cohort study monitoring safety in patients with Multiple Sclerosis recently initiated with fingolimod once daily or treated with another approved disease-modifying therapy, Novartis, prot. CFTY720D2406
- Transition: A two-year observational study to evaluate the safety profile of fingolimod in patients with Multiple Sclerosis who switch from natalizumab to fingolimod, Novartis, prot. CFTY720D2405
- A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis Novartis, prot. CFTY720D2399
- A 18-months, open label, rater-blinded, randomized, multicenter, active-controlled, parallel group pilot study to assess efficacy and safety of Fingolimod in comparison to Interferon Beta 1-B in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy, CFTY720DIT01
- An open-label, multicenter, expanded access study with Fingolimod in patients with Relapsing Remitting Multiple Sclerosis for whom no suitable therapy exists, CFTY720DIT03,
- Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis CFTY720D2306E1
- A multicenter, randomized, double-blind, placebo-controlled study of the efficacy of Natalizumab on reducing disability progression in subjects with Secondary Progressive Multiple Sclerosis, with optional open-label extension, Biogen, prot. 101MS326
- A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive Multiple Sclerosis, Novartis, prot. CBAF312A2304
- A Phase 2/3, Multi-Center, Randomized, Double-Blind, placebo-controlled (Part A) and double-blind, double-dummy, active-controlled (Part B), parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing Multiple Sclerosis patients, Receptos, prot. RPC1063
- A prospective observational study to depict the role of adherence as a tool of treatment decision making in RMS subject experiencing first clinical relapse with 1st line DMDs (CHOICE)
- A randomized, multicountry study to evaluate the effectiveness of florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline (AVID)
- Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month trial of leuco-methylthioninium bis (hydromethanesulfotane) in subjects with Mild to moderate AD, TauRx Therapeutics Ltd, prot. Trx-237-015
- Observational, single-arm, multicenter, one-day trial, in Relapsing Remitting MS patients to characterize the population for whom extended monitoring after the first dose of Fingolimod was necessary, CFTY720DIT08 - BEAT
- Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil, Lundbeck, 14861A
- A 24-month, multicenter, randomized, double-blind, placebo-controlled, parallel- Group, efficacy, safety, tolerability, biomarker and pharmacokinetic of AZD3293 in early Alzheimer's disease (The AMARANTH study)

- A multinational, multicenter, randomized, parallel Group, open-label study to assess medication satisfaction in patient with Relapsing Remitting Multiple Sclerosis (RRMS) treated with subcutaneous injection of Copaxone 40 mg/mL Three Times a Week compared to 20 mg daily (TY44400)
- An open-label study to evaluate the efficacy and safety of Ocrelizumab in patients with Relapsing Remitting Multiple Sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment (MA30005)
- FORTE – GA/9016 A multinational, multicenter, randomized, parallel-group, double-blind study, to compare the efficacy, tollerabilità and safety of glatiramer acetate injection 40mg/ml to that of glatiramer acetate injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (R-R) multiple sclerosis (MS)
- AVE625 Sanofi A double blind placebo-controlled study of the activity of AVE 1625 at doses of 10 mg and 40 mg for 12 weeks in patients with mild to moderate Alzheimer's diseases. STUDY ACT10019
- AVA102672 – Glaxo - Studio di 54 settimane, randomizzato, in doppio cieco, controllato con placebo, a gruppi paralleli, mirato a valutare gli effetti di rosiglitazone (comprese a rilascio prolungato) come terapia aggiuntiva a donepezil sulle funzioni cognitive e sulla risposta clinica globale, in soggetti stratificati secondo il genotipo APOE 4, con malattia di Alzheimer di grado lieve-moderato (REFLECT-2)
- AVA102675 – Glaxo - A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer's disease (REFLECT-4)
- AZ3110866 – Glaxo- Study AZ3110866, a fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
- ENA713 Exelon Patch Rivastigmine CENA 713D2340 - Novartis – A 48-week, multicenter, double-blind, parallel-group evaluation of the comparative efficacy, safety and tolerability of Exelon 10 and 15 cm² patch in patients with Alzheimer's disease showing cognitive decline during an initial open-label treatment phase.
- Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with relapsing remitting multiple sclerosis in treatment with interferon-beta-(ARIANNA) – Multicenter, randomised, double blind, placebo controlled, parallel-group-study. Studio Schering – prot. DR04-07-02
- An active extension of LAQ/5062 study – multinational, multi-center, randomised, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3mg and 0.6mg) of laquinimod, orally administered in relapsing-remitting (R-R) multiple sclerosis (MS) subjects. Teva Pharmaceutical Industries. Prot. N. LAQ/5063
- A randomised controlled trial to assess the efficacy of a food for special medical purposes (FSMP) in patients with mild Alzheimer's disease – Souvenir II trial – Danone, prot. Alz.1.C/D

6) **Membro editorial board di rivista internazionale**

- 2006-2014: Journal of Neurology
- 2008-oggi: Therapy
- 2010-oggi: Journal of Alzheimer's disease
- 2005-2015: Journal of the Neurological Sciences
- 1990-2002: Journal of the Peripheral Nervous System
- 2010-oggi: Neurological Reviews

7) **Altro ruolo organizzativo**

- 2002-oggi: membro del Consiglio Scientifico del Centro Dino Ferrari per lo studio delle malattie neuromuscolari e neurodegenerative dell'Università di Milano
- 2005: Socio Fondatore SinDem (Società per lo studio delle demenze afferente alla Società Italiana di Neurologia)
- 2008-2010, 2012-oggi: consigliere Sindem
- 2010-2012: Segretario Sindem
- 2007-2013. Membro eletto della Executive Committee della European Neurological Society (ENS)
- 2004-2006: Membro Comitato Scientifico Associazione Italiana Sclerosi Multipla
- 2014-oggi: membro Consiglio Direttivo dell'Associazione Italiana per la Ricerca sull'Invecchiamento Cerebrale (AIRIC)
- 2008-oggi: membro del Consiglio Scientifico Fondazione Monzino
- 2014-oggi: membro dell'Eli Lilly International Advisory Board

- 2017-oggi: membro del Merck Sharp & Dome International Advisory Board
- 2014-oggi: membro eletto dell'Assemblea dei Delegati della European Neurological Academy (EAN)

8) **Organizzazione eventi scientifici**

- XXXVII Annual Meeting of the Italian Neuropathological Association, Teaching course on demyelinating diseases “Demyelination in PNS and CNS: basic mechanisms and advances in treatment” May 23, 2001, Verbania, Italy
- A tribute to Professor Guglielmo Scarlato - “Immunology of Multiple Sclerosis: from molecular pathogenesis to treatment” – 1 febbraio 2003, Milan, Italy.
- Patogenesi e clinica delle malattie demielinizzanti – Corso biennale residenziale
I anno: Aspetti patogenetici e diagnostici – 2-5 Marzo 2004, Milano
II anno: Aspetti prognostici e terapeutici – 2-4 Marzo 2005, Milano
- Giornata monotematica del Centro di Eccellenza per le Malattie Neurodegenerative dal titolo: “Nuove acquisizioni nella neurobiologia della malattia di Alzheimer: implicazioni pratiche per una diagnosi ed un trattamento precoci” – Milano, 28 Ottobre 2006.
- “Demenza di Alzheimer e malattia di Parkinson”- Milano, 25 Novembre 2010
- VII Congresso Annuale della Associazione Italiana per lo studio delle Demenze afferente alla Società Italiana di Neurologia (SINdem) – Milano, 17-19 Marzo 2011

9) **Relazioni su invito a congressi internazionali**

- “Treatment of Alzheimer’s disease” - XII Meeting of the European Neurological Society, June 22-26, 2002, Berlin, Germany
- “Dementia update: the treatment of MCI and AD” - Teaching course, XIV Meeting of the European Neurological Society, June 26-30, 2004, Barcelona, Spain
- Alzheimer’s Disease Expert Input Forum, May 13, 2005, Frankfurt, Germany - Expert for Italy
- Educational Forum for the Diagnosis and Treatment of Alzheimer’s Disease with Cerebrovascular Disease February, 18-19, 2005, Berlin, Germany – Italian opinion leader
- Exelon InDDEx Data Review Meeting. April 11, 2005, Miami, USA. Member of the Steering Committee
- “Inflammation and Alzheimer’s disease: genetic aspects” - 41st Annual Meeting of the Italian Association of Neuropathology (AINP) jointly with the French Society of Neuropathology – 31st Meeting of the Italian Association for Research on Brain Aging (AIRIC), May 26-28, 2005, Saluzzo, Italy
- Teaching Course on “Treatment of Alzheimer’s disease” - XVI Meeting of the European Neurological Society, May 27-31, 2006, Lausanne, Switzerland
- Plenary Symposium “Behavioural disorders in Neurology” - XVII Meeting of the European Neurological Society, June 2007, Rhodes, Greece
- Symposium “Behavioural disturbances in frontotemporal lobar degeneration: recent advances in molecular genetics and neurobiology”- XVIII Meeting of the European Neurological Society, Nice, June 7-11, 2008
- Teaching course “Treatment of dementias: facts and perspectives”, XIX Meeting of the European Neurological Society, Milan, June 20-24, 2009
- Teaching course “Biological bases of new treatments for Alzheimer’s disease” - XX Meeting of the European Neurological Society, Berlin, Germany, June 19-23, 2010
- Teaching course “Anticholinesterases: more of the same?”- XIV Meeting of the European Federation of Neurological Societies, Geneva, Switzerland, September 25-28, 2010
- “Immunotherapy of Alzheimer’s disease” - Meeting “A tribute to R. Lisak”, Detroit, USA, May 18, 2012
- “Standard pharmacotherapy of AD: do's and don'ts” - XVI Congress of the European Federation of Neurological Societies - Stockholm, Sweden, September 08-11, 2012
- Symposium “Recent advances in Alzheimer’s disease and other dementias: treatment perspectives”. XXIII meeting of the European Neurological Society, Barcelona, June 8-11, 2013
- Focused Workshop “Old and new proteinopathies: Tau and TDP-43” 1st Congress of the European Academy of Neurology, Berlin, June 2015

10) **Chairman congressi internazionali**

- XII Meeting of the European Neurological Society, June 22-26, 2002, Berlin, Germany – Oral session “Higher function disorders”

- XIII Meeting of the European Neurological Society, June 14-18, 2003, Istanbul, Turkey – Oral session “Higher function disorders”
- XIV Meeting of the European Neurological Society, June 26-30, 2004, Barcelona, Spain – Oral session “Higher function disorders”, June 29th
- XV Meeting of the European Neurological Society, June 18-22, 2005, Vienna, Austria – Oral session “Multiple Sclerosis”, June 20th.
- “Educational Forum for the Diagnosis and Treatment of Alzheimer’s disease with Cerebrovascular Diseases” organized by Merck Sharp & Dome – personal invitation as Opinion Leader – Friday, May 13th, 2005, Frankfurt, Germany
- “Exelon InDDEx Data Review Meeting” organized by Novartis – personal invitation as member of the InDDEx Steering Committee – April 11th, 2005, Miami Beach, USA
- XVI Meeting of the European Neurological Society, June, May 27-31, 2006 Lausanne, Switzerland – oral session “Higher Function Disorders”
- XVIII Meeting of the European Neurological Society, Nice, June 7-11, 2008 - poster session on dementia
- XX Meeting of the European Neurological Society, Berlin, Germany, June 19-23, 2010- oral session on dementia
- XXI Meeting of the European Neurological Society, Lisbon, Portugal, May 28-31, 2011, oral session “Dementia: clinical and neuro.imaging”
- XVI Congress of the European-Federation-of-Neurological-Societies (EFNS) - Stockholm, Sweden September 08-11, 2012 – Poster session on Dementia

Attività gestionale e clinico-assistenziale presso la Fondazione Ca’ Granda, IRCCS Ospedale Maggiore Policlinico

- 1995-oggi: Responsabile del Centro per la Dispensazione dei Farmaci Immunomodulanti per la Sclerosi Multipla riconosciuto con Decreto Regionale
- 2000-oggi: Responsabile Centro UVA (Unità Valutativa Alzheimer), riconosciuto con Decreto Ministeriale
- 2003-2013: Responsabile UOS Malattie Neurodegenerative e Demielinizzanti
- 2012-oggi: Responsabile del “Centro di Riferimento malattia di Alzheimer e demenze correlate” della Fondazione Ca’ Granda, IRCCS Ospedale Policlinico
- 2012-oggi: Responsabile del “Centro di Riferimento Sclerosi Multipla” della Fondazione Ca’ Granda, IRCCS Ospedale Policlinico
- 2013-oggi: Direttore della UOSD Neurologia-Malattie Neurodegenerative
- 2013-oggi: Direttore del Laboratorio di Diagnostica Neurochimica e Genetica Molecolare della UOSD Malattie Neurodegenerative
- 2013-oggi: Responsabile del MAC/DH della Neurologia

Data

30/11/2017

Luogo

Milano